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The deposition of misfolded peptides and proteins in the form of amyloid ﬁbrils is the hallmark of nearly
ﬁfty medical disorders, including Alzheimer's disease, Parkinson's disease, prion diseases and type II
diabetes. These disorders, referred to as amyloidoses, generally become apparent late in life. Their
psycho-sociological and economic incidence in western societies will be therefore considerable in the
coming decades due to the ageing of the population. Neither preventing nor curative treatments are
available yet. These disorders constitute therefore a medical challenge of great importance. Thus, an
extensive research is being carried out to understand, at the molecular level, (i) how amyloidogenic
proteins misfold and convert from their soluble form into amyloid ﬁbrils, and (ii) how these aggregates
or some of their oligomeric precursor species are toxic. The formation of amyloid ﬁbrils proceeds through
a complex nucleation/polymerisation mechanism with the formation of various species, including small
oligomers. In this review, we focus on how VHHs or nanobodies, the antigen-binding domains of camelid
heavy-chain antibodies, are being increasingly used to characterise each of the species formed on the
pathway of ﬁbril formation in terms of structure, stability, kinetics of formation and toxicity. We ﬁrst
introduce the characteristic features of nanobodies compared to those of conventional antibody frag-
ments. Thereafter, we discuss how nanobodies, due to their unique properties, are used as probes to
dissect the molecular mechanisms of misfolding and aggregation of six proteins associated with diseases,
i.e. human lysozyme, b2-microglobulin, a-synuclein, prion, polyadenylate binding protein nuclear 1 and
amyloid b-peptide. A brief general presentation of each disease and the associated peptide/protein is also
provided. In addition, we discuss how nanobodies could be used as early diagnostic tools and as novel
strategies to treat diseases associated with protein misfolding and aggregation.
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The amino acid sequence of each protein newly synthetised by
ribosomes contains all the information required for the protein to
acquire its native tridimensional structure and, therefore, its func-
tional biological state. Nature has in fact developed sophisticated
mechanisms to ensure the correct folding of proteins, including the
evolution of speciﬁc polypeptidic sequences or the involvement of
factors such as folding catalysts and molecular chaperones [1]. The
latter help the polypeptide chains to correctly and efﬁciently fold
but they do not however determine the ﬁnal native conformation of
the protein. Despite these mechanisms, some proteins, however,
fail to fold correctly or to maintain their native state, because of
different factors such as mutations or increased concentration.
These proteins are normally rapidly recognised by the quality
control system and degraded by the proteasome or other proteo-
lytic machineries [2]. In spite of these quality control and degra-
dation machineries, the probability that some proteins fail to adopt
or to maintain their functional conformation is however not
negligible. Given the crucial roles of proteins in virtually any cellular
processes, this failure generally leads to serious diseases which are
known as protein conformational diseases or protein misfolding
diseases [3,4]. In some cases, not only misfolded proteins are not
anymore able to exert their normal biological activity (and this
could be the direct cause of some diseases such as in cystic ﬁbrosis
[1]), but they can also interact with each other to form pathological
insoluble, highly organised and stable aggregates called amyloid
ﬁbrils. The formation of such aggregates is associated with nearly
ﬁfty diseases referred to as amyloidoses [3].
Amyloidoses are neurodegenerative or non-neuropathic,
depending on whether the amyloid ﬁbrils deposit in the nervous
system or in other tissues or organs; in the latter case, the disease
can be localised (i.e. affecting only one organ) or systemic (i.e.
affecting various organs) [3]. The most common neurodegenerative
amyloidoses are Alzheimer's disease (AD) and Parkinson's disease
(PD). Amyloidoses generally appear late in life; due to the rising
ageing of the population, they inﬂict enormous psycho-sociological
and economic burdens on western societies and constitute there-
fore a great medical challenge. These age-associated disorders
indeed affect several million people per year. For example, it is
estimated that, in 2005, between 4.1 and 4.6 million individuals
were living with Parkinson's disease in the 15 more populated
nations worldwide, and this number will double by 2030 [5]. Ac-
cording to a report published in 2013, Alzheimer's disease is the
sixth leading cause of all deaths in the United States. An estimated
5.2 million Americans have AD and, by 2050, the incidence of AD is
expected to approach nearly a million new cases per year, with a
total estimated prevalence of 13.8 million people [6]. So far, there is
no preventive or curative therapy for these devastating pathologies,
and the current treatments only alleviate the symptoms without
modifying the course of the diseases. For example, in the case of AD,
acetylcholinesterase inhibitors are used to reduce the loss of
acetylcholine caused by the death of cholinergic neurons [7]. For
the patients suffering from PD, most treatments aim at correcting
the deﬁciency of the brain neurotransmitter dopamine [8]. There is
therefore an intensive worldwide research effort to shed light on
the mechanisms, at the molecular level, of protein misfolding and
aggregation and their link to pathology. The identiﬁcation of all the
various species formed during the complex process of ﬁbril for-
mation as well as their characterisation in terms of structure, sta-
bility, kinetics of formation and toxicity are essential to develop
some early diagnostic tools and to identify targets for therapeutic
treatments.
Each amyloidosis is associated with the aggregation of a
particular peptide or protein into amyloid ﬁbrils (for exampleAb-peptide (Ab) and Tau protein in Alzheimer's disease, a-syn-
uclein (aSyn) in Parkinson's diseases and islet amyloid poly-
peptide (IAPP) in type II diabetes). The disease-associated
proteins differ widely in their sequence, size and native struc-
ture; in their aggregated form, however they all share a similar
highly organised structure, rich in b-sheets and known as cross-
b structure [9]. Fibril formation is a complex phenomenon,
generally described as a nucleation/polymerisation process,
characterised by a sigmoidal growth proﬁle (Fig. 1). This process
involves a variety of conformational rearrangements and multi-
ple steps of assembly [3,4]. First, a slow nucleation step is
characterised by a lag phase; it involves the misfolding of the
proteins into aggregation prone species (also referred to as
amyloidogenic intermediate) and the association of these species
into various oligomeric species, leading to the formation of
nuclei or seeds of aggregation. These oligomers, also called pre-
ﬁbrillar species, are structurally diverse and some of them have
been found to be more cytotoxic than mature ﬁbrils [10]. During
the polymerisation step (or elongation phase), the nuclei rapidly
expand by addition of monomers or oligomers to form proto-
ﬁbrils and ﬁnally ﬁbrils. In the ﬁnal steady state or stationary
phase, ﬁbrils and monomers are in equilibrium and the structure
of the ﬁbrils can still evolve for example by rearrangement of the
region of the protein that is not part of the core of the ﬁbrils,
leading to mature ﬁbrils [11]. Besides, the amyloid ﬁbrils can also
associate laterally [12]. The lag phase can be shortened or even
suppressed by the addition of seeds (i.e. preformed oligomers or
ﬁbrils), a phenomenon known as seeding [13]. Moreover,
increasing evidence suggests that once a critical concentration of
ﬁbrils has formed, the primary nucleation/polymerisation
pathway described above can be dominated by secondary
pathway(s) such as ﬁbril fragmentation, lateral growth and/or
ﬁbril-catalysed secondary nucleation [14e16]. Finally, recent
ﬁndings suggest a prion-like spreading of amyloidogenic pro-
teins: aggregates of tau, aSyn, Ab and huntingtin have indeed
been found to be capable of moving between cells and trigger
the misfolding of their normal conformers [17].
Because of their insoluble character, their heterogeneity in size
and quantity, and/or their transient feature, the characterisation of
most of the species formed upon ﬁbril formation is extremely
challenging. Indeed, these species cannot be easily studied by most
of the conventional techniques available for soluble proteins
because these require concentrated and homogeneous samples
which are difﬁcult to obtain for each individual intermediate spe-
cies. Since a given protein generally adopts a different conformation
in its native, oligomeric and amyloid forms, the development of
speciﬁc and sensitive structural (or conformational) molecular
probes for the characterisation of these distinct forms is therefore a
very valuable approach. Monoclonal conformational antibodies can
be extremely promising for this purpose since they could in prin-
ciple be speciﬁcally raised against any conformational state of
peptides or proteins [18e21]. Moreover, as illustrated in this re-
view, the extent of their speciﬁcity can be adjusted through the
judicious choice of antigens and of the screening procedures.
Antibodies can be used in several ways to investigate the
mechanism of ﬁbril formation. For example, the binding properties
of a series of antibodies speciﬁcally raised against various epitopes
at the surface of the native state of a protein can be compared
before and after the conformational changes leading successively to
amyloidogenic intermediates, oligomeric species and mature ﬁbrils
[21,22]. In this way, the regions of the protein that are structurally
reorganised can be identiﬁed at each step. Alternatively, partial
unfolding events expose to the solvent some regions of the protein,
normally buried within the native fold; antibodies raised against
such epitopes will therefore recognise amyloidogenic
Fig. 1. Schematic model describing the aggregation process of an amyloidogenic protein, the species that are bound or not bound by the nanobodies, and the steps at which the
nanobodies inhibit the process of aggregation. The formation of amyloid ﬁbrils consists of three phases: (i) a nucleation phase, during which monomers undergo conformational
change (i.e., they misfold) and associate to form oligomeric nuclei, (ii) an elongation phase, during which the nuclei rapidly grow by further addition of monomers or oligomers to
form protoﬁbrils and ﬁbrils, and (iii) a stationary phase, where monomers and ﬁbrils are in equilibrium and during which ﬁbrils can mature. The grey boxes indicate the species
which the different nanobodies bind to, the crossed-out grey boxes indicate the species that are not recognised by the different nanobodies, and the blue boxes indicate the steps
inhibited by the various nanobodies. M, monomers; MM, misfolded monomers; D, dimers; N, nuclei; PF, protoﬁbrils; F, ﬁbrils; MF, mature ﬁbrils.
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such an approach can provide information on the structurewhich is
adopted by the region(s) of the protein involved in the unfolding
event [21]. Finally, antibodies recognising epitopes that are generic
of oligomeric species or amyloid ﬁbrils have also been described
[23e26]. Thus, from a mechanistic point of view, the use of these
various speciﬁc antibodies could in principle allow to map the
apparition of each species in time and can allow a detailed com-
parison of the aggregation pathways under different conditions
including events occurring in vivo [27].
Several antibody formats have been used as structural and
mechanistic probes to investigate the aggregation process of
diverse proteins: whole mice monoclonal antibodies [28], anti-
body fragments such as Fab [25], scFv [29,30] and VH [31], and
recently, the variable domains of heavy-chain antibodies, referred
to as nanobodies or VHHs. In this review, we report the main re-
sults of the studies involving the latter antibody format. We ﬁrst
introduce the characteristic features of nanobodies compared to
those of conventional antibody fragments such as Fab, Fv and scFv.
Then, we discuss how nanobodies, thanks to their unique proper-
ties, have been used as structural and mechanistic probes to
dissect the mechanisms of misfolding and aggregation of a series
of proteins associated with amyloid or conformational diseases.
This last part is divided into six sections corresponding to six
targets, i.e. human lysozyme (HuL), b2-microglobulin (b2m), a-
synuclein (aSyn), prion (PrP), polyadenylate binding protein nu-
clear 1 (PABPN1) and amyloid b-peptide (Ab). In addition, we
discuss how nanobodies can be used as early diagnostic tools andto design novel strategies to treat diseases associated with amyloid
ﬁbril formation.2. Unique properties of nanobodies
2.1. Nanobody, the smallest natural antigen-binding fragment
Nanobodies correspond to the variable domains of camelid
heavy-chain antibodies (HCAbs). HCAbswere discovered in 1989 by
the group of R. Hamers [32] during a practical experiment con-
ducted by undergraduate students at the Free University of Brus-
sels, Belgium [33]. These IgG antibodies lack light chains and the
ﬁrst constant domain of the heavy chains (i.e., the CH1 domains)
present in their conventional counterparts; HCAbs are composed
therefore of only two heavy chains (Fig. 2, central part). They are
synthetised by Camelidae (including camels, llamas and drome-
daries) in addition to conventional antibodies and their proportion
depends on the species: HCAbs represent 50% of the IgG in drom-
edaries and camels and 25e45% in llamas [32,34,35]. The antigen-
binding domain of HCAbs is naturally reduced to a single domain of
~130 amino acids (~14 kDa) and it therefore corresponds to the
smallest available natural antigen-binding fragment; it is referred
to as nanobody, VHH or single-domain antibody (sdAb). In spite of
their small size, nanobodies bind to their antigens with high afﬁnity
(i.e. in the nanomolar range) and speciﬁcity [36,37]. In this review,
we use the term VHHs when structural features are concerned,
otherwise we use the denomination nanobodies.
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The tridimensional structure of VHHs corresponds to a typical
immunoglobulin fold. It is composed of nine b-strands organised
into two b-sheets, stabilised by a conserved disulphide bridge be-
tween Cys23 and Cys94 (IMGT numbering [38]) (Fig. 2, central
part). The amino acid sequence of VHHs presents a high degree of
identity (~80%) with the human VH3 (variable domain of the heavy
chain of conventional antibodies) gene family [34,39,40]; it has
however evolved to compensate for the absence of the VL domain
as follows:
(i) Four hydrophobic amino acids, conserved among all VHs,
are substituted by more hydrophilic residues in the VHH
sequences (V42F or V42Y, G49E, L50R and W52G, IMGT
numbering) [41,42] (Fig. 2, central part). These amino acids
are located in the framework 2 (FR2), corresponding to the
region of the VH domain that interacts with the VL (variable
domain of the light chain) domain in conventional anti-
bodies. By decreasing the hydrophobicity of the surface ofFig. 2. Overview of the unique properties and characteristics of nanobodies. Central pa
Conventional antibodies contain two light chains (represented in blue and composed o
(represented in yellow and composed of one variable domain (VH) and three constant do
The VH and VL domains form the Fv fragment; when these two domains are linked tog
devoid of the light chains and of the CH1 domains. The 3D structure of a VHH is shown as w
and in the sequence, the frameworks (FR) are shown in green and CDR1, CDR2 and CDR3 a
acids that are substituted by more hydrophilic residues in the VHH sequences (V42F or V
VHH sequence and are highlighted in orange in the structure. The continuous blue lines in
blue line represents the additional disulphide bridge present in many VHHs. The external
between hen-egg white lysozyme (HEWL, grey) and the nanobody cAb-Lys3 (brown). The
from Ref. [50]).VHH that is exposed to the solvent due to the absence of
the VL, these mutations allow VHHs to be soluble in the
absence of the VL domain.
(ii) The complementarity determining regions (CDRs, i.e. re-
gions of the antibody that interact with the antigen) of
VHHs are longer than those of VHs, and particularly the
CDR1 and CDR3 (Fig. 2, central part). The average length
of the CDR3 from human VHs is 12 residues while that
from dromedary VHHs contains most frequently ~16e18
amino acids [34,43]. Several VHHs with CDR3 longer than
25 residues have been reported [44,45]. The larger size of
the CDRs is believed to compensate for the absence of the
three CDRs from the VLs (the antigen is recognised by
only three CDRs instead of six in conventional antibodies)
and therefore provide a sufﬁciently large antigen-
interacting surfaces of 600e800 Å2 [46]. CDRs of VHHs
also adopt a larger variety of conformations, compared to
the CDRs of VHs [47e49]. Together, these two character-
istics allow a broad antigen-binding repertoire, counter-
balancing the lack of VHeVL combinatorial diversity.rt: Schematic representation of the conventional and heavy-chain antibodies (Ab).
f one variable domain (VL) and one constant domain (CL)) and two heavy chains
mains (CH1, CH2 and CH3)). The VH, CH1, CL and VL domains form the Fab fragment.
ether by a small peptide, they form the scFv fragment. Heavy-chain antibodies are
ell as a schematic representation of the sequence of VH and VHH. In the 3D structure
re shown respectively in blue, violet and red. The position of the four hallmark amino
42Y, G49E, L50R and W52G, IMGT numbering) are indicated by orange stars on the
dicate the conserved disulphide bridge, shown in both VH and VHH, and the broken
parts highlight the very unique properties of the VHHs. # 3D structure of the complex
long CDR3 of cAb-Lys3 (blue) protrude into the active site of HEWL (Figure adapted
Table 1
Afﬁnity of HuL-speciﬁc nanobodies and their engineered counterparts for Wt-HuL.
The afﬁnity and the Tm of the nanobodies under buffer conditions (pH 5.5, 3 M
urea and 48 C) used to induce the formation of amyloid ﬁbrils by the I56Tand D67H




KD (nM) (pH 5.5, 3
M urea & 48 C)
Tm (C) (pH 5.5, 3
M urea & 48 C)
cAb-HuL6 0.7 10 75 ± 1
cAb-HuL22 35 ND 49 ± 2
cAb-HuL22-S54C/I78C 50 ~1000 66 ± 1
cAb-HuL5 460 ND 66.0 ± 0.5
cAb-HuL5G 310 2500 77.5 ± 0.5
I56T and D67H lysozyme 56 ± 1
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allowing VHHs to bind unique conformational epitopes,
such as cryptic epitopes, clefts or cavities that are
generally inaccessible to conventional VHeVL pairs [50]
(Fig. 2, left part, #). Since this kind of epitopes is often
associated with the function of proteins (e.g. enzyme
active sites), nanobodies can thus be used to modulate
biological activities [51]. As the CDR3 generally contrib-
utes from 50 to 100% of the antigen-interacting surface
[34], it is easy to design and synthetise constrained
peptides that mimic the CDR3 structure and retain the
speciﬁcity/activity of the nanobody (i.e. enzyme in-
hibitors, receptor agonists or antagonists) [52].
(iii) An additional disulphide bond is present in many VHH
sequences, especially those originating from dromedaries;
it is generally located between CDR1 and CDR3 (64%) but
can also be located between CDR3 and FR2 [39]. In gen-
eral, VHHs with longer CDR3 have a higher probability to
contain an additional disulphide bridge [37]. This disul-
phide bond probably restricts the ﬂexibility of long CDRs,
which is expected to be entropically counterproductive
for binding, and therefore allows a strong interaction [53].
Moreover, it may also enable CDRs to adopt new confor-
mations enabling VHHs to recognise an increased variety
of epitopes [40,54].
2.3. Nanobodies are easy to generate, select and produce
Nanobodies can be obtained from immune, naive or synthetic
libraries [34] (Fig. 2, upper part). In the ﬁrst case, an animal is
immunised with the antigen of interest and, after 5 or 6 weekly
injections, lymphocytes are isolated from the peripheral blood.
cDNAs are prepared from total extracted RNA, and those encoding
VHH genes are selected by PCR as described by Muyldermans [34].
Since the entire antigen-binding fragment of HCAb consists of one
domain, encoded by a gene fragment of only ~360 bp that is easily
ampliﬁed by PCR, small libraries of ~106e107 individual trans-
formants are already representative of the immune repertoire
[46]. Naive libraries are generated in the same manner from the
blood of a non-immunised animal, while synthetic libraries are
created, for example, by randomly mutating the amino acids
belonging to CDR3 of a VHH exhibiting a robust scaffold [55,56].
Some residues of the CDR3, that are essential to maintain its
conformation, must be conserved to ensure the proper folding of
the mutant VHHs [34]. The use of naive or synthetic libraries is
particularly interesting in the case of toxic, pathogenic or non-
immunogenic antigens, or for antigens that are not available in
sufﬁcient quantities for immunisation [34]. They need however to
be much larger (~109 individual clones) than immune libraries to
allow the retrieval of high-afﬁnity binders [46]; once prepared, the
advantage of these libraries is that they can in theory be used to
select binders against any target.
In all cases, antigen-speciﬁc nanobodies are retrieved from
these libraries by phage display or other selection protocols such
as bacterial display [57], yeast display [58] or ribosome display
[59]. Due to its robustness, the phage display method is the most
often used one. The VHH genes, ampliﬁed by PCR, are generally
cloned into an appropriate vector (phagemid) at the 30-end of a
gene coding for a coat protein of a ﬁlamentous phage (generally
M13) [34]. VHHs are then expressed at the tip surface of the
phages and the most speciﬁc binders are panned on antigens
which are most of the time immobilised in wells of a microtiter
plate by passive adsorption or biotinylated on streptavidin-
coated solid supports. Generally, two to three rounds of
panning are sufﬁcient to enrich the population of antigen-speciﬁc nanobodies compared to the non-speciﬁc ones. Nano-
bodies repertoires present a great advantage over those of con-
ventional antibodies: they do not need the random combination
of VH and VL chains which lead to the generation of many non-
productive combinations due to the loss of the original pairing
[34]. Moreover, the whole procedure is also much less time and
money consuming.
Finally, the selected nanobodies can be expressed recombinantly
with a high yield in bacteria (~40e70 mg per litre of culture)
[60,61], yeast (>100 mg per litre of culture) [62,63] or plants (up to
30% total leaf proteins) [64,65]. Their puriﬁcation is usually ach-
ieved by immobilised metal ion afﬁnity chromatography (IMAC) via
an engineered C-terminal His6 tag, or by other afﬁnity chroma-
tographies as nanobody gene is easily cloned in another vector to
change the tag [60].
2.4. Nanobodies are highly stable entities
Nanobodies exhibit a high resistance to temperature (tem-
perature of mid-denaturation, Tm, generally comprised between
60 and 80 C), chaotropic reagents (concentration of mid-
denaturation, Cm, generally comprised between 2.3 and 3.3 M
guanidinium chloride and between 5.8 and 9 M urea) or high
pressure (pressure of mid-denaturation comprised between 600
and 750 MPa), and have high conformational stabilities (DG
(H2O) comprised between 30 and 60 kJ mol1) [37,66]. Conse-
quently, nanobodies can be stored at 4 C for months and
at 20 C for years without losing their ability to bind to their
antigen. They can also tolerate incubation at 37 C for a long
period (i.e. more than one week) in PBS [67] or even in plasma
(i.e. no decrease in activity is observed after an incubation for
44 h in mouse plasma, [68]). The fact that nanobodies exhibit a
high stability is especially important for their use as molecular
probes to study the process of amyloid ﬁbril formation because
denaturing conditions and/or long incubation time (up to several
weeks) need generally to be used to trigger the in vitro aggre-
gation of target proteins. Finally, their high stability allows most
of nanobodies to be easily concentrated to 1e15 mg mL1 in
standard buffers [46] and to be freeze-dried without losing their
functionality [37,69].
2.5. The properties of nanobodies are easily improved using protein
engineering
Since VHHs are composed of only one single-domain of ~130
amino acids, and thus are encoded by a short gene fragment,
their properties (i.e. afﬁnity, stability, immunogenicity, etc.) can be
easily and straightforwardly improved by protein engineering in
comparison with the more complex conventional antibody frag-
ments such as Fab and scFv. For example, the stability of a particular
C. Pain et al. / Biochimie 111 (2015) 82e106 87VHH that has a high afﬁnity for an antigen of interest but a poor
stability, can be improved either by adding a new disulphide bridge
between the two beta-sheets of its framework (i.e. between resi-
dues 54 and 78, IMTG numbering) [70,71] or by grafting its CDRs to
another robust VHH scaffold [72] (Table 1). Moreover, due to their
small size, nanobodies can be used as modular building blocks for
manifold constructs to create (i) multivalent (i.e. by linking two or
more nanobodies recognising the same epitope), (ii) multispeciﬁc
(i.e. by linking two or more nanobodies recognising different epi-
topes) or (iii) multifunctional (i.e. by linking one nanobody to an
enzyme or toxin) entities for research, immuno-diagnosis or ther-
apy (for a review, see Ref. [73]) (Fig. 2, lower part). As exempliﬁed in
the next sections, some of these engineering strategies have been
essential to adapt the properties of nanobodies to the investigation
of the mechanism of amyloid ﬁbril formation.
3. Nanobodies as structural probes to investigate the
molecular mechanism of amyloid ﬁbril formation
3.1. Human lysozyme and systemic amyloidosis
Human lysozyme is associated with a hereditary systemic
amyloidosis. So far, seven amyloidogenic variants have been iden-
tiﬁed: I56T, Y54N, F57I, W64R, D67H, F57I/T70N and T70N/W112R
(Fig. 3A) [74,75]. All the patients are heterozygous, the disease
being transmitted through an autosomal dominant mechanism.
This disease is associated with the aggregation of one lysozyme
variant into amyloid ﬁbrils that accumulate extracellularly into
several tissues and organs (including liver, kidneys, spleen,
gastrointestinal tract and salivary glands) [76,77]. The age at which
amyloid deposits appear, their distribution in tissues and the clin-
ical features are very variable both within and between families
[76].
Human lysozyme is a 130 amino acid muramidase (MM
~14.7 kDa), which is widely distributed in a variety of tissues and
body ﬂuids including liver, articular cartilage, plasma, saliva, tears
andmilk [78]. It is constituted of two domains: the a-domainwhich
contains four a-helices (named A, B, C and D) and two short 3e10
helices, and the b-domain which contains a short 3e10 helix, a b-
sheet (containing 3 strands) and a long loop. The active site is
located at the interface between the two domains (Fig. 3A).
The amyloidogenic I56T and D67H variants and the non-
amyloidogenic T70N variant have been well characterised. Their
structure, stability, folding kinetics and in vitro aggregating prop-
erties have been compared to those of the wild type protein (Wt-
HuL). The three mutations are localised within the b-domain: the
I56T mutation is near the active site, while the D67H and T70N
mutations are localised in the loop (Fig. 3A). X-ray diffraction
studies showed that the structure of the I56T variant is identical to
that of the Wt-HuL while the D67H mutation disrupts three
hydrogen bonds involving residues Y54, K69 and T70. The
destruction of this hydrogen-bonding network results in a rear-
rangement of part of the b-domain: the long loop and two b-
strands of the b-domain move away from each other [79] (Fig. 3A).
A similar rearrangement, although of lower amplitude, is also found
in the X-ray structure of the non-amyloidogenic T70N natural
variant [80]. These observations therefore indicate that there is no
direct correlation between the structural changes induced by the
mutations in the native state of lysozyme and the propensity of the
variant proteins to form amyloid ﬁbrils.
The I56T and D67H mutations, despite their different locations
and effects on the structure of the protein, decrease to a similar
extent the thermostability of the lysozyme. Their Tm are about 10 C
lower relative to the wild-type protein at all the pH values tested
(i.e. from 2.5 to 7) [76], while the naturally occurring non-amyloidogenic T70N variant is destabilised by only ~4 C [80].
Hydrogen/deuterium (H/D) experiments analysed by mass spec-
trometry and nuclear magnetic resonance (NMR) show that the
signiﬁcant destabilisation of the I56T and D67H variants allows
them to populate transiently an intermediate species under phys-
iologically relevant conditions of temperature and pH (Fig. 3D). In
this species, the b-domain and the C-helix (referred to as the
amylotope [44]) are cooperatively unfolded while the rest of the a-
domain remains native [81,82] (Fig. 3A). Such a species is formed
neither by the Wt-HuL nor by the non-amyloidogenic T70N variant
under the same conditions [80,81]. Thus, the formation of this in-
termediate species under physiological relevant conditions, due to
a decrease in global cooperativity (i.e. the protein does not unfold
anymore as a single entity), is a characteristic feature underlying
the amyloidogenicity of the I56T and D67H lysozyme variants. The
formation of intermolecular interactions between the unfolded
parts of the intermediate species is likely the trigger event of am-
yloid ﬁbril formation (Fig. 3E).
3.1.1. HuL speciﬁc nanobodies cAb-HuL5, cAb-HuL6 and cAb-
HuL22: generation, characterisation and engineering
The pioneering study of using nanobodies as structural probes to
investigate amyloid ﬁbril formation was actually carried out with
human lysozyme [69]. The choice of nanobodies was dictated by
their high stability. Indeed, the amyloidogenic lysozyme variants
must be incubated under rather harsh denaturing conditions (i.e. in
0.1 M citrate buffer pH 5.5 containing 3 M urea at 48 C or in 0.1 M
acetate buffer pH 5.0 at 65 C) to form amyloid ﬁbrils in vitro in a
reasonable time [69,82]; thus, in order to use antibody fragments as
molecular structural and mechanistic probes they must be stable
and functional under those conditions.
Three nanobodies (named cAb-HuL5, cAb-HuL6 and cAb-HuL22)
have been selected by phage display from the blood of a dromedary
immunised with the monomeric Wt-HuL; this protein was also
used for the panning [37,44,83]. These nanobodies bind to three
different epitopes on the surface of lysozyme (Fig. 3B) with afﬁn-
ities in the nanomolar range (Table 1). The structures of cAb-HuL5
and cAb-HuL6 in complex with Wt-HuL have been determined by
X-ray crystallography. The epitope of cAb-HuL5 (i.e. the residues of
HuL that are in direct contact with the nanobody) consists of 14
residues of the lysozyme molecule, located primarily on the loop
between the A and B helices [83]; it does not encompass any res-
idue from the amylotope (i.e. the region involved in the cooperative
local unfolding event characteristic of the I56T and D67H variants)
(Fig. 3A). The epitope of cAb-HuL6 encompasses 14 residues located
in the loop between the A and B helices in the a-domain, in the long
loopwithin the b-domain and in the C-helix; 11 of these 14 residues
belong to the amylotope (Fig. 3A) [69]. No crystallographic data is
available for cAb-HuL22. However, several results such as (i) surface
plasmon resonance (SPR) competition experiments with an
analogue substrate, (ii) the lower afﬁnity for D67H compared to
that for Wt-HuL, and (iii) the comparison of NMR heteronuclear
single quantum coherence (HSQC) spectra of 15N-Wt-HuL free and
in complex with cAb-HuL22 suggest that cAb-HuL22 binds into the
active site of the protein through its long CDR3 loop (i.e. containing
29 residues) [44]. Thus, the epitope of cAb-HuL22 likely encom-
passes some residues from the amylotope (Fig. 3A).
cAb-HuL6 is more thermostable that both the I56T and D67H
variants and can bind them under the conditions used to form ﬁ-
brils in vitro (e.g. 0.1 M citrate buffer pH 5.5 containing 3 M urea at
48 C) [69,82,83] (Table 1). On the contrary, cAb-HuL22 is less
thermostable than the lysozyme variants and could therefore not
be used to inhibit ﬁbril formation [44]. Thus, in order to increase
the stability of this nanobody, one of the strategies shown to efﬁ-
ciently improve nanobodies stability was used: a disulphide bond
Fig. 3. Mechanism of aggregation of HuL into amyloid ﬁbrils and mechanisms of inhibition of this process by cAb-HuL5, cAb-HuL6 and cAb-HuL22. (A) Overlay of ribbon diagrams
representing the structures of Wt-HuL (grey) and the D67H variant (green); the structure of the I56T variant is indistinguishable from that of Wt-HuL. The a-helices are labelled
AeD and the four disulphide bonds are shown in blue. The Ca atoms of the amyloidogenic mutations 54, 56, 57, 64 and 67 are represented as red spheres. The T70N and W112R
mutations, coloured in violet, are not associated with disease unless they are in combination with a substitution at another position (F57I/T70N and T70N/W112R). The large blue
arrow indicates the location of the active site. The black arrows show the regions of the molecule [i.e. the two beta-strands and the long loop of the b-domain] that are signiﬁcantly
distorted in the D67H variant compared to those of the Wt-HuL and I56T proteins. The regions of the I56T and D67H variants that unfold transiently in a cooperative manner are
coloured in dark grey and dark green, respectively. The lysozyme structures were generated from coordinates determined by X-ray diffraction studies [PDB 1LYY (D67H), 1LOZ (I56T)
and 1LZ1 (Wt-HuL)] and produced using MOLMOL. (B) Ribbon diagram representing the structure of Wt-HuL and showing the epitopes of the nanobodies. The epitope of cAb-HuL5
and cAb-HuL6 are shown by black and green spheres, respectively; the amino acid that is common to both is shown in cyan. cAb-HuL22 was shown to bind into the active site,
although the epitope could not be determined by X-ray crystallography. The labels are identical to those in panel (A). (C) Kinetics of aggregation of the D67H in the absence ( ) and
in the presence of the cAb-HuL6 (left) and cAb-HuL5 (right) ( ). The aggregation has been followed by the changes in light scattering. The ratio between D67H and the nanobody is
indicated. (D) Detection of the transient unfolding intermediate of lysozyme in the absence and the presence of nanobodies by hydrogen/deuterium (H/D) exchange experiments
monitored by mass spectrometry. In these experiments, lysozyme molecules were ﬁrst fully deuterated and the exchange monitors the loss of deuterons (that are replaced by
hydrogens) over time. The peaks coloured in black are those observed in the spectra of control samples recorded after complete H/D exchange. The peaks coloured in green arise
from the exchange of deuterium atoms through localised structural ﬂuctuations, whereas those coloured in yellow arise from the cooperative unfolding of the C-helix and the b-
domain. These latter peaks are not observed in the mass spectra of the D67H variant in the presence of cAb-HuL6, indicating that the binding of this nanobody restores the global
cooperativity of the D67H variant. The same inhibition was observed for cAb-HuL6 and the I56T variant [82], and for cAb-HuL22 and both the I56T and D67H variants [44]. On the
other hand, these yellow peaks are observed in the mass spectra of the D67H variant in the presence of cAb-HuL5; the binding of cAb-HuL5 does therefore not inhibit the
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mutations (IMGT numbering) [70,71]. The variant obtained (named
cAb-HuL22-S54C/I78C) is signiﬁcantly more thermostable (i.e. its
Tm is 17 C higher than that of cAb-HuL22) and its afﬁnity for Wt-
HuL, at least at 25 C in 10 mM HEPES buffer pH 7.5, is in the
same order of magnitude that of cAb-HuL22 [44] (Table 1). Finally,
although cAb-HuL5 is more thermostable than I56T and D67H
lysozyme variants, it signiﬁcantly aggregates under the conditions
used to trigger the aggregation of the latter [83]. A less aggregation-
prone version of cAb-HuL5 was therefore engineered by grafting its
CDRs onto the extremely stable scaffold of cAb-HuL6; the chimeric
nanobody obtained is referred to as cAb-HuL5G. cAb-HuL5G is more
stable than cAb-HuL5: its Tm, in 0.1 M citrate buffer pH 5.5 con-
taining 3 M urea, is increased by ~9.5 C (i.e. 75.5 C versus 66.0 C)
(Table 1). Moreover, the binding parameters of cAb-HuL5G to Wt-
HuL are similar to those measured for cAb-HuL5 at pH 7.5 and
25 C (Table 1).
These examples highlight the main advantage of nanobodies,
compared to conventional antibody fragments, to investigate the
mechanism of amyloid ﬁbril formation (Fig. 2). Indeed, their sta-
bility and solubility can be straightforwardly and easily improved
by protein engineering techniques, without impairing their binding
properties, to make them functional under the relatively harsh
conditions that are often used to trigger in vitro aggregation of
protein over a reasonable timeframe.
3.1.2. cAb-HuL5, cAb-HuL6 and cAb-HuL22 as mechanistic probes
3.1.2.1. The binding of the three nanobodies inhibits the amyloid ﬁbril
formation of human lysozyme variants. In the presence of an equi-
molar amount of cAb-HuL6, the D67H (Fig. 3C) and I56T [69,82]
variants of lysozyme do not signiﬁcantly aggregate, even after
24 h of incubation, while both variants completely aggregate into
amyloid ﬁbrils in less than 5 h when incubated in the absence of
nanobodies [69,82]. The binding of cAb-HuL22-S54C/I78C and cAb-
HuL5G to D67H also signiﬁcantly inhibits ﬁbril formation although,
due to their low afﬁnity under the conditions used to trigger
lysozyme ﬁbril formation, a high nanobody/lysozyme ratio (i.e. 5/1
for cAb-HuL22-S54C/I78C [44] and 11.2/1 for cAb-HuL5G [83]) is
needed (Fig. 3C).
3.1.2.2. cAb-HuL5 inhibits human lysozyme ﬁbril formation through a
mechanism different from that of cAb-HuL6 and cAb-HuL22.
H/D exchange experiments analysed by mass spectrometry have
shown that the binding of cAb-HuL6 (Fig. 3D) and cAb-HuL22 [44]
prevents the formation of the intermediate species by both the
D67H (Fig. 3D) and I56T variants [82]. These results suggest that
these nanobodies inhibit the ﬁbril formation by restoring the global
cooperativity of the variants that is characteristic of the wild-type
lysozyme. Moreover, they further support the fact that the forma-
tion of the partially unfolded lysozyme intermediate triggers the
formation of amyloid ﬁbrils. The crystal structure of the cAb-HuL6/
Wt-HuL complex indicates that only 11 residues of the nearly 60
involved in the transient cooperative unfolding of the I56T and
D67H variants are in direct contact with the nanobody. Thus, the
effects of the binding of cAb-HuL6 is not just to mask the entire
region that is destabilised by themutation and hence to prevent the
unfolding from the rest of the structure [69]. Comparison of thecooperative unfolding event. The same absence of inhibition was observed with the I56T va
nanobodies. Partially unfolded intermediate species of the protein (i.e. the amyloidogenic i
associate through the unfolded regions to initiate the formation of oligomers and ultimate
of amyloid ﬁbrils by stabilising the native state of the amyloidogenic variants of lysozyme an
not prevent the formation of the amyloidogenic intermediate; it is likely to inhibit the reo
intermediate but disorganised in the ﬁbrils. Note that the native disulphide bridges, tho
Figure adapted from Refs. [44,69,83].NMR HSQC spectra of the lysozyme variants alone and in complex
with the nanobodies has allowed the long-range effects of nanobody
binding to be mapped. Note that the small mass of the nanobodies
and thus the limitedmass of the complex prevents an excessive loss
of the NMR signal and thus allows identifying peaks whose
chemical shift is signiﬁcantly perturbed upon the binding of the
nanobody. This analysis shows that ~30 residues of lysozyme
exhibit a signiﬁcant change in chemical shift upon binding of cAb-
HuL6, most of them are located in positions directly in contact with
the nanobody or in close proximity to the latter. A few affected
residues are however far from the binding site and reﬂect a long
range effect through the backbone. They include residues 56 and 57
which are locations of the I56T and F57I amyloidogenic mutations
and that are essential for the integrity of the interface between the
a- and b-domains the protein [69,82]. It was therefore proposed
that the binding of cAb-HuL6 to the amyloidogenic variants restores
the global cooperativity characteristic of the wild-type protein
through, at least in part, long-range subtle conformational effects
which stabilise the interface between the two structural domains of
the protein. The same mechanism of action was proposed for cAb-
HuL22 that binds into the active site of the protein [44].
By contrast, the binding of cAb-HuL5 does not prevent the for-
mation of the intermediate species by both the D67H (Fig. 3D) and
I56T variants [83]; it does not, therefore, restore the global coop-
erativity of the lysozyme variants. The effects of the binding of a
nanobody on the properties of the interface between the a- and b-
domains, and thus on the global cooperativity of the amyloidogenic
lysozyme variants, are therefore highly dependent on the epitope.
Moreover, these results suggest that this cAb-HuL5 could act at a
later stage on the process of ﬁbril formation (Fig. 3E). cAb-HuL5
does not bind to human lysozyme in its ﬁbrillar form, indicating
that its epitope does not maintain its native state in the aggregated
form of lysozyme. Thus, cAb-HuL5, which binds to the a-domain of
the lysozyme, is thought to inhibit the formation of amyloid ﬁbrils
by preventing the unfolding of the a-domain, the latter event is
therefore a crucial step in the formation of amyloid ﬁbrils by human
lysozyme [83].
3.1.3. Conclusions
The results obtained with cAb-HuL5, cAb-HuL6 and cAb-HuL22
indicate that nanobodies can inhibit the formation of amyloid ﬁbrils
at different stages of the process of amyloid ﬁbril formation. This
pioneering work has demonstrated the value of nanobodies as
structural probes to study the molecular mechanisms of amyloid
ﬁbril formation.
3.2. b2-Microglobulin and dialysis-related amyloidosis
The dialysis-related amyloidosis (DRA) is associated, at least in
part, with the increase in b2-microglobulin (b2m) concentration
(up to 60-fold) during long-term haemodialysis, which leads to the
aggregation of b2m into insoluble amyloid ﬁbrils that accumulate
extracellularly in bones and joints [84,90,91]. This deposition
causes painful arthropathy, cysts and pathologic fracture. Up to
~30% of the b2m found in these aggregates are actually a truncated
form lacking the six N-terminal amino acids (DN6b2m) [85,86].
Recently, another form of b2m amyloidosis was discovered, inriant [83]. (E) Proposed mechanism for lysozyme ﬁbril formation and its inhibition by
ntermediate) in which the C helix and the b-domain are cooperatively unfolded, self-
ly of amyloid ﬁbrils. The binding of cAb-HuL6 and cAb-HuL22 inhibits the formation
d thus preventing the transient unfolding event to occur. The binding of cAb-HuL5 does
rganisation of the regions of the a-domain that are native-like in the amyloidogenic
ugh not represented in this scheme, are present in all species including the ﬁbrils.
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of b2m aggregates into amyloid ﬁbrils whose deposition is not
restricted to musculo-skeletal system but also occurs in viscera
(i.e. in spleen, liver, heart and salivary glands) and nerves, mainly
around endoneurial capillaries and within vessel walls [84]. Con-
trary to DRA, the patients suffering from this hereditary systemic
amyloidosis have normal renal function and a normal circulating
b2m concentration [84]. The D67N pathogenic variant, unlike the
wild-type protein, has a very high propensity to form amyloid ﬁ-
brils in vitro under physiologically relevant pH and temperature
conditions.
b2m is a 130 amino acid protein (MM ~11.7 kDa) corresponding
to the light chain of the type I major histocompatibility complex
(MHC-1) [87]. The MHC-I molecules are responsible for antigen
presentation in a process controlling the immune response against
“self” and “non-self” antigens. b2m is expressed on the surface of
nearly all nucleated cells and it adopts an immunoglobulin fold,
made up of a seven-stranded b-sandwich linked by a disulphide
bridge (Fig. 4E, left part) [88,89]. Although the increased concen-
tration of b2m is a decisive factor in causing DRA, it is not sufﬁcient
by itself. The nature of the other factor(s) that trigger(s) the for-
mation of b2m amyloid ﬁbril is still a matter of intense debate. They
include the age of the patient, duration of renal dysfunction, in-
teractions with a range of molecules (e.g. copper ions, glycosami-
noglycans and collagen), and the formation of one or more
amyloidogenic intermediates [90,91]. A b2m conformer with a non-
native peptidyl-Pro32 trans peptide bond is, in particular, thought
to serve as a direct precursor of dimeric species and oligomers that
accumulate in the early phase of ﬁbril formation [92]. The exposure
of Trp60, which is located in the DE loop, upon dissociation of b2m
from the MHC-1 complex may also play a critical role in promoting
ﬁbril formation [93].
3.2.1. Generation and characterisation of b2m speciﬁc nanobodies
A series of eight nanobodies has been selected by phage display
from the blood of camel and llama immunised with the monomeric
humanWt-b2m or DN6b2m; these two proteins were also used for
the panning [94]. The afﬁnities of these nanobodies for b2m and its
DN6 variant are in the nanomolar range (Fig. 4D).
3.2.2. Nanobodies as mechanistic probes: inhibition of b2m amyloid
ﬁbril formation
The ability of nanobodies to inhibit ﬁbril formation was investi-
gated using DN6b2m, since this protein has a greater in vitro pro-
pensity to form amyloid ﬁbrils than the full length b2m [95]. When
incubated at pH 5, 37 C, in the presence of salt, DN6b2m is rapidly
(i.e. within 124 h) converted into ‘non-amorphous aggregates’ that
bind thioﬂavin-T (ThT); after 2weeks of incubation, theﬁrst amyloid
ﬁbrils start to grow out of these aggregates while all aggregates are
converted into amyloid ﬁbrils after 4 weeks [94]. Remarkably, in the
presence of a 12% excess of ﬁve of the eight nanobodies, DN6b2m,
incubated at 37 C, does not aggregatewithin 124 h (Fig. 4AeC). One
of the nanobodies, Nb24, when added in an equimolar amount, can
even disrupt preformed DN6b2m ‘non-amorphous aggregates’,
leading to an increased soluble fraction of the truncated protein.
Nb24 is, however, unable to dissociate preformed DN6b2m amyloid
ﬁbrils.
3.2.3. Nanobodies as structural probes: structure of the nucleus for
b2m ﬁbrillogenesis
The ﬁve inhibitory nanobodies were tested as co-crystallisation
chaperones of DN6b2m but diffracting crystals were obtained
only for the complex with Nb24 [94]. Under the conditions of
crystallisation of the complex, the DN6b2m alone aggregates
within minutes, indicating that the nanobody indeed serves as anefﬁcient crystallisation chaperone. The crystal structure obtained at
high resolution (2.2 Å) reveals that the DN6b2m variant forms a
domain-swapped dimer exchanging residues 91e94 which forms
the G-strand. This G-strand swap is accompanied by the extension
of the hinge loop of each monomer which interact to each other to
form of a new b-sheet composed of two anti-parallel b-strands
(Fig. 4E, right part). The extended hinge loop corresponds to the
heptapeptide NHVTLSQ (residues 83e89) and very interestingly,
the polypeptide NHVTLS has been found to have an intrinsic high
tendency to form short ﬁbrils in vitro [96]. Moreover, in the
DN6b2m domain-swapped dimer, the backbone NH and CO groups
of V85 and L87 are exposed to the solvent, and therefore are prone
to interact with b-strands of other swapped dimers or opened
monomers (i.e. with the extended hinge loop). In addition, while in
b2m monomer Pro32 adopts the cis conformation, it adopts a trans
conformation into the domain-swapped dimer; as mentioned
above, this non-native peptidyl-Pro32 trans peptide bond is
thought to be a critical event in the initiation of the aggregation
process. Altogether, these observations suggest that the domain-
swapped dimer could act as a plausible nucleus for b2m ﬁbrillo-
genesis, which can recruit other swapped dimers or opened
monomers by a self-templated mechanism. The binding of Nb24
could prevent the aggregation of b2m by steric hindrance, by mass
action or by prohibiting potential structural changes in the core of
b2m (Fig. 4F).
Nb24was also used as crystallisation aid to solve the structure of
P32Gb2m, a non-natural variant of b2m that has a higher pro-
pensity than the wild-type protein to form amyloid ﬁbrils in vitro
[97]. In this case, b2m crystallises as a monomer in complex with
Nb24. Like in the swapped dimer formed by DN6b2m, the peptide
bond at position 32 also adopts a trans conformation in P32Gb2m in
complex with Nb24 while Pro32 adopts a cis conformation in the
wild-type protein. The trans conformation in position 32 in
P32Gb2m causes several structural rearrangements that may in-
crease the susceptibility of the protein to aggregate into amyloid
ﬁbrils [97]. In particular, the b-strand D is less kinked in P32Gb2m
than in wild-type b2m and is therefore more prone to intermo-
lecular pairing. It also leads to the rearrangement of several hy-
drophobic residues and to a concomitant increase in the surface
hydrophobicity that could also contribute the increased propensity
of P32Gb2m to form amyloid ﬁbrils [97].
3.2.4. Detection of the b2m in the MHC-I at the surface of cells
Nb24 does not bind to b2m within the MHC-I complex exposed
on the surface of human cells [94]. Thus, this nanobody efﬁciently
blocks the formation of amyloid ﬁbrils without interfering with the
biological function of b2m. This suggests that Nb24 could be
developed as a therapeutic tool to prevent amyloid deposits in
dialysis patients; it remains however to demonstrate that the
species stabilised by Nb24 are not toxic.
3.2.5. Conclusions
Altogether, these two studies involving Nb24 and two variants
of b2m supports that the Pro32 cis to trans switch is determinant
for the aggregation of b2m into amyloid ﬁbrils [97]. Moreover, they
demonstrate that nanobodies can be used as chaperones to trap
transient amyloidogenic intermediate species and allow their
structural characterisation at atomic resolution
3.3. Human a-synuclein and Parkinson's disease
Parkinson's disease (PD), familial or sporadic, is the second most
common age-related neurodegenerative disorder, affecting about 1%
of the population over the age of 70 [98]. It is characterised by tremor,
slowness of movements, muscular rigidity and impairment of
Fig. 4. Effects of the binding of eight nanobodies on DN6b2m ﬁbrillogenesis. DN6b2m (DN6) was incubated at 42.5 mM for 1 week at 37 C in 50 mM sodium acetate, pH 5.0, in the
absence or the presence of excess amount (50 mM) of each nanobody (Nb108, a b2m-unrelated nanobody raised against another antigen, is used as a negative control). The kinetics of
ﬁbrillogenesis were monitored by: (A) measuring the increase in ThT ﬂuorescence after 0, 24, and 124 h, (B) analysing remaining soluble proteins (i.e. protein remaining in the
supernatant after centrifugation) by SDS-PAGE, and (C) visualising the aggregates formed after 124 h by transmission electron microscopy (TEM). The binding of Nb22, Nb23, Nb24,
Nb30 and Nb272 signiﬁcantly inhibits the aggregation of DN6b2m. (D) KD (nM) of nanobodies for b2m and DN6b2m as measured by surface plasmon resonance. (E) Ribbon
representations of the b2mmonomer (left) compared to the domain-swapped dimer of DN6b2m crystallised in the presence of Nb24 (right). In the swaped dimer, the two extended
hinge loops fold into a new two-stranded anti-parallel b-sheet. The conserved disulﬁde bond that bridges the two sheets of b2m are shown as stick. (F) Possible model of b2m
ﬁbrillogenesis mechanism and of its inhibition by Nb24. The self-association of two open b2m monomers by domain swapping generates a dimeric intermediate which can serve as
a structural nucleus for ﬁbrillogenesis. The ends of growing oligomers can recruit open monomers or swapped dimers by a mechanism of self-templated growth. The dashed red
circle represents the epitope of Nb24; the binding of the nanobody could prevent the amyloidogenesis of b2m by steric hindrance, by mass action or by prohibiting potential
structural changes in the core of b2m, thus preventing the elongation of oligomers. Figure adapted from Ref. [94].
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progressive loss of dopaminergic neurons in the substantia nigra pars
compacta of the brain, associated with the formation of intracellular
ﬁbrillar inclusions known as Lewy bodies (LB) and Lewyneurites. These inclusions are essentially made of a-synuclein (aSyn)
[99].
aSyn is a relatively small (140 aa) and soluble intracellular
protein which is especially abundant in neural tissues [100]. The
C. Pain et al. / Biochimie 111 (2015) 82e10692normal cellular function of aSyn is not clearly determined yet [101];
it has however been suggested that it has a role in the regulation of
synaptic function, plasticity and neurotransmission release [102].
Several studies have indicated that aSyn may also act as chaperone
for the formation of presynaptic SNARE (soluble N-ethylmaleimide-
sensitive-factor attachment protein receptor) complexes; SNARE
are transmembrane proteins that mediate the fusion of synaptic
vesicles [103,104]. A number of genetic mutations, including A30P,
E46K and A53T (Fig. 5A), and the triplication of the aSyn gene are
correlated with early onset of the disease [105]. Extensive experi-
mental data indicate that aSyn belongs to the family of natively
unfolded proteins, characterised by a lack of typical secondary
structures and thus of tightly packed tertiary structure [106]. A
recent study has, however, suggested that it might form, in the cell,
a dynamic tetramer that is not prone to aggregation [107]. Three
regions can be distinguished in the aSyn sequence [106,108]
(Fig. 5A). (i) An N-terminal segment (residues 1e60) which is
positively charged and contains imperfect repeats of 11 residuesFig. 5. Effects of the binding of NbSyn2 and NbSyn87 on the properties of aSyn. (A) Sche
imperfect KTK(E/Q)GV repeats (i.e. R1eR4) which are crucial for the interaction with memb
vesicles. This region also contains the 3 mutations that are associated with familial PD. (ii) Th
in amyloid ﬁbril formation. This region also contains two imperfect repeats (R5eR6). (iii) Th
interaction of aSyn with various binding partners and to solubilise and prevent the protei
amyloid ﬁbrils are shown in red (1e30 and 110e140). The binding site of NbSyn2 and NbSyn
NbSyn87 with seeded and unseeded aSyn ﬁbrils at different stages of maturation by ITC. ITC
panel, F0,2d) and 6 days (Central panel, F0,6d) of incubation at 25 C, compared with seeded ﬁ
of NbSyn87 for the ﬁbrils left to evolve and mature in solution for 6 days (F0,6d) is decreased.
molecule take place upon the maturation of the ﬁbrillar state. The data for the binding of
molecular equivalent of injected nanobody; this proﬁle contrasts with the classical monoto
between unseeded (F0) and seeded (F1) ﬁbril samples are therefore likely to indicate struct
and without NbSyn2, monitored by ThT binding assays. The nanobodywas added at 1 equiva(R1eR4), each with a high propensity to form amphipathic helices
upon interaction with lipids. (ii) A central hydrophobic region
known as the NAC (non-Ab component) region (residues 61e95)
which is believed to be responsible for the formation of ﬁbrils.
Mutation of only one residue in the NAC region signiﬁcantly per-
turbs the aggregating properties of the protein [109]. And (iii) a
polar and negatively charged C-terminal region (residues 96e140)
which also contains 5 prolines. The presence of negatively charged
residues and prolines at the C-terminus suggests that this region
has a tendency to remain in disordered conformation. This domain
is, however, thought to regulate the aggregation process by
shielding the NAC region [110].
Under aggregation-prone conditions, the monomeric protein
changes from either a-helical lipid-bound, helically folded tetramer
or intrinsically disordered conformation towards highly ordered b-
sheet ﬁbrillar structure. As for other diseases, increasing evidence
suggests that the oligomeric precursors and pre-ﬁbrillar species,
owing to their ability to interact with membranes, are primarilymatic representation of aSyn. (i) The N-terminal region contains the majority of the
ranes. It adopts an a-helical conformation upon binding to biological membranes and
e NAC region in the central part of the protein has been shown to play an essential role
e C-terminal part corresponds to the acidic region and is thought to be involved in the
n from aggregation. The regions that are highly ﬂexible and solvent accessible in the
87 are shown in green and blue, respectively. (B) Characterisation of the interactions of
experiments with NbSyn87 added to unseeded ﬁbril samples isolated after 2 days (Left
bril samples isolated after 2 days (Right panel, F1,2d) of incubation. The apparent afﬁnity
These results suggest that conformational rearrangements of these regions of the aSyn
NbSyn87 to seeded (F1) ﬁbrils reveal a bimodal proﬁle of the integrated heat versus
nic binding proﬁle observed for unseeded ﬁbrils. The differences in binding isotherms
ural differences. Figure adapted from Ref. [11]. (C) Kinetics of aggregation of aSyn with
lent (yellow squares) and 0.1 equivalent (green triangles). Figure adapted from Ref. [27].
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mature ﬁbrils [111,112]. Several studies have shown that amyloid
ﬁbrils of aSyn consist of intertwined protoﬁlaments, each consist-
ing of a ﬁve-stranded b-sheet, leaving residues 1e30 and 110e140
highly ﬂexible and solvent accessible (Fig. 5A). Although these N-
and C-terminal regions are not directly involved in the assembly of
the protoﬁlament core, and do not adopt a b-sheet conformation,
they play a key role in the interactions between the protoﬁlaments,
which is necessary for their stabilisation and ﬁbril maturation [113].
3.3.1. aSyn speciﬁc nanobodies NbSyn2 and NbSyn87: generation
and characterisation
Two nanobodies, speciﬁc to aSyn, have been isolated by phage
display from the blood of dromedary [27] and llama [11] immu-
nised with the monomeric human Wt-aSyn or the natural amy-
loidogenic variant A53T-aSyn. These nanobodies are named
NbSyn2 and NbSyn87, and they both bind to the soluble form of a-
synuclein in a 1:1 binding stoichiometry with nanomolar afﬁnity
(i.e. KD ¼ 14.2 ± 8.4 and 129.8 ± 22.7 nM for NbSyn87 and NbSyn2,
respectively). Circular dichroism experiments show that the
binding of both nanobodies does not induce signiﬁcant changes in
the secondary structure of aSyn. Their epitopes were mapped by
NMR, comparing the HSQC spectra of the 15N-aSyn alone and in
the presence of increasing concentrations of the unlabelled
nanobodies. Importantly, as for lysozyme, thanks to the small size
of the nanobodies, the complex has a limited mass that prevents an
excessive loss of the NMR signal and thus allows the epitope to be
straightfowardly mapped. The titration of aSyn by both nanobodies
results in either broadening or chemical shift perturbations of
resonances; the amino acids that display the most signiﬁcantly
perturbed resonances are 118e137 and 130e140 for NbSyn87 and
NbSyn2, respectively, both belonging to the C-terminal region of
aSyn (Fig. 5A). The study of the interaction of NbSyn87 with a
series of peptides spanning the aSyn sequence from residues 118
to 140 further indicates that the majority of the epitope recognised
by NbSyn87 is located between residues 118 and 131, and that
residues 118 and 119 are critical for binding [11]. The crystal
structure of NbSyn2, bound to a peptide corresponding to the last
9 residues of aSyn, reveals that only the last four amino acids of
aSyn (137e140) are in direct contact with the nanobody forming a
linear epitope [27].
3.3.2. NbSyn2 and NbSyn87 as structural probes
Isothermal titration calorimetry (ITC) and quartz crystal mi-
crobalance (QCM) data indicate that both nanobodies can bind, even
simultaneously, to the aSyn amyloid ﬁbrils, indicating that their
speciﬁc epitopes, encompassing the C-terminal domain of aSyn, are
exposed to the solvent in the ﬁbrils [11,27]. An NMR experiment, in
which increasing concentrations of 15N-labelled NbSyn2 were
added to the suspension of a-Syn amyloid ﬁbrils, shows that, one
average, four molecule of aSyn in the ﬁbril interact with only one
molecule of NbSyn2. This ratio could be explained by the steric
hindrance of NbSyn2, i.e. one molecule of NbSyn2 could prevent
the binding of another molecule of NbSyn2 on the nearest a-syn-
uclein C-termini [27]. Another possibility is the fact that the ma-
jority of C-terminus residues of a-synuclein are buried within the
ﬁbrils. This latter possibility is supported by the structure of ﬁbrils,
in which only one in four termini is accessible to the solvent [27].
ITC experiments carried out with unseeded ﬁbrils (i.e., ﬁbrils
formed in the absence of seeds) obtained after 2 days (F0,2d) show
that the apparent afﬁnities of both nanobodies are lower than those
measured for the soluble monomer of aSyn (Fig. 5B). Very inter-
estingly, the apparent afﬁnity of both nanobodies for the same ﬁ-
brils left to evolve andmature in solution for 6 days (F0,6d) is further
decreased (Fig. 5B). Moreover, the proﬁle of the integrated heatversus molecular equivalent of injected nanobody for the binding of
both Nb2 and NbSyn87 to seeded ﬁbrils (F1, i.e. ﬁbrils formed in the
presence of seeds) is bimodal (Fig. 5B) whereas a classical mono-
tonic binding proﬁle was observed for the binding to unseeded ﬁ-
brils (F0). The different binding isotherms between unseeded and
seeded ﬁbrils are therefore likely to indicate structural differences
between the two types of ﬁbrils. Therefore, these results suggest
that conformational rearrangements of the C-terminal region of the
aSyn molecule take place upon the maturation of the ﬁbrillar state.
No differences between F0,2d, F0,6d and F1 ﬁbrils were observed by
other techniques such as ThT binding or TEM indicating that
nanobodies are able to target forms of potentially pathogenic ag-
gregates that differ from each other by relatively minor details of
their structures [11].
3.3.3. Nb2Syn as a mechanistic probe
NbSyn2 does not signiﬁcantly inﬂuence the kinetics of aSyn
amyloid ﬁbril formation (Fig. 5C) suggesting that the last four C-
terminal residues of aSyn (137e140) do not play a part in the
structure or stability of any intermediate species whose formation
affects the aggregation kinetics [27]. At an equimolar concentration
of NbSyn2/aSyn, the kinetics of amyloid ﬁbril formation, probed by
ThT ﬂuorescence, exhibits however a shorter lag-phase (~2.5 h)
(Fig. 5C) and a higher number of shorter ﬁbrils is observed. Thus, in
the presence of the nanobody, the rate of ﬁbril fragmentation seems
higher, explaining the shorter lag phase in the aggregation reaction
probed by ThT ﬂuorescence.
3.3.4. Conclusions
Altogether, these studies demonstrate that nanobodies can act as
powerful molecular probes to gain insights into the structure of
amyloid ﬁbrils and probe relatively minor structural changes upon
their maturation that cannot be observed by other techniques.
Moreover, since it does not interfere with ﬁbril formation, NbSyn2
can be used as a silent structural probe to investigate the exposure
of C-termini in various species along the pathway of ﬁbril formation
and in mature ﬁbrils. This silent probe could allow the study of the
inﬂuence of the environment on the pathway of ﬁbril formation
through the structural rearrangement of the aSyn C-terminus re-
gion in the different species.
3.4. Prion and prion diseases
Prion diseases, also known as transmissible spongiform en-
cephalopathies (TSEs), are a family of progressive transmissible
neurodegenerative diseases that affect humans and animals. The
major neuropathological hallmarks of TSEs are extensive spongio-
sis, neuronal loss in the central nervous system, gliosis and depo-
sition of amyloid ﬁbrils [114]. TSEs are a family of diseases with a
wide variety of clinical manifestations including psychiatric
symptoms such as agitation, behavioural disturbance, hallucination
and difﬁculty walking and speaking [115,116]. TSEs are associated
with the conversion of the normal cellular prion protein (PrPC) into
b-sheet-rich scrapie conformers (PrPSc) which aggregate into am-
yloid ﬁbrils and deposit extracellularly, leading to neuronal death
and spongiform changes in the brain parenchyma. The most com-
mon human prion disease form is the sporadic Creutzfeldt-Jakob
disease with one or two new patients per million and per year
worldwide [117]; moreover, more than 40 mutations in the prion
protein lead to hereditary autosomal dominant form of the disease
[117]. The disease can also be transmitted to humans by eating
diseased meat, by receiving corneal transplants from infected do-
nors and through contaminated medical equipment [118]. Ac-
cording to the protein-only-hypothesis, PrPSc is the essential
causative agent of prion disease and transmission, acting as a truly
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conformational template to promote the conversion of PrPC into
PrPSc and to propagate the pathology from cell to cell, from tissue to
tissue, and even between hosts for some TSEs [119]. Despite the fact
that PrPC and PrPSc have the same amino acid sequence, they differ
in several aspects. Unlike PrPC, PrPSc (i) is insoluble in non-ionic
detergents, (ii) is partially resistant to proteinase K digestion, and
(iii) presents an increased content in b-sheet structure [120].
Human PrPC is a 208 amino-acid glycoprotein widely expressed
in various tissues; the highest levels of PrPC are found in neurons
but it can be found in other organs including spleen, kidneys, heart
and lungs [121]. Mature PrPC is found predominantly anchored by
glycosyl-phosphatidylinositol to the extracellular cell surface.
Although a clear-cut function for PrPC in the central nervous system
(CNS) is yet to be established, a role in memory is probable [121]. In
the peripheral nerves, PrPC appears to have an important contri-
bution in myelin maintenance. PrPC might also be involved inFig. 6. Effects of the binding of PrioV3 and Nb484 on the properties of prion. (A) Schematic
before post-translational modiﬁcations. Signal sequences in the amino- and carboxy-termin
(23e231). The protein is divided in two domains: (i) an N-terminal ﬂexible domain contain
two-stranded anti-parallel b-sheet, and containing one disulphide bridge and two glycosylat
(B) Crystal structure of the full length HuPrP (23e231) in complex with Nb484. The structur
parallel b-sheet is highlighted in yellow. Note that the disordered tail (residues 23e116) and
Ref. [125]. (C) PrioV3 inhibits the accumulation of PrPSc in ScN2a cells. ScN2a cells were incu
camel); untreated cells were also included. The cells were then lysed and subsequently tre
sandwich ELISA in triplicates. Both concentrations of PrioV3 used to treat ScN2a cells show
control and the untreated cells. PrioV3 also leads to decreased levels of normal prion prote
antibody-treated mice. Mice were inoculated with RML (Rocky Mountain Laboratory) scrap
intraperitoneal injections of 2 mg PrioV3 or CD71 (control antibody) for 60 days. Treatment w
replication did not occur in CD71-treated as well as untreated mice. Adapted from Ref. [126].
revealed with anti-llama IgG (green) and anti-mouse IgG (red) antibodies, respectively. Prio
ICSM35 strictly stains cell membrane-bound PrP (blue arrow). Adapted from Ref. [126].numerous biological activities including cell-signalling, neuro-
genesis, neuroprotection and synpaptic transmission [121]. PrPC is
composed of two domains [122] (Fig. 6A): (i) a ﬂexible disordered
N-terminal domain (residues 23e124) including several octapep-
tide repeats (60e91) and a positively charged segment (residues
96e111), and (ii) a structured globular C-terminus (residues
125e231) containing three a-helices, two of them being linked by a
disulphide bridge and two very short anti-parallel b-strands. This
b1-a1-b2-a2-a3 anti-parallel b-ribbon structure is referred to as
the PrPCelike fold in the Structural Classiﬁcation of Protein (SCOP)
database [123]. Conversion of PrPC into PrPSc is associated with
simultaneous loss of a-helix content and considerable gain of b-
sheet structure which correlates with the characteristic partial
resistance to proteinase K (residues 90 to 231 become resistant to
proteolysis). There is a lot of evidence indicating that important
structural changes also occur in the N-terminal region (i.e., in the
region incompassing residues 90e120), and particularly in therepresentation of human prion. The primary sequence of PrP is 253 amino acids long
al ends are removed post-translationally, resulting in a mature length of 208 residues
ing 5 octarepeats and (ii) a globular C-terminal domain made of three a-helices and a
ion sites. The binding sites of Nb484 and PrioV3 are shown in blue and red, respectively.
ed part of HuPrP (residues 117e231) is shown in crimson and the three-stranded anti-
the C-ter residues 226e231 are not visible. The Nb484 is shown in cyan. Adapted from
bated for 24 h at 37 C with 1 or 25 mg PrioV3, 25 mg NCS (serum from non-immunised
ated or not with proteinase K prior to analysis of respectively PrPSc and PrPC levels by
a signiﬁcant decrease in prion replication (P < 0.001) when compared with the NCS
in. Adapted from Ref. [126]. (D) PrioV3 antibody inhibits PrPSc replication in spleens of
ie brain homogenate and, 10 days after the inoculation, they were treated with weekly
ith PrioV3 induces a drastic decrease in splenic PrPSc levels; inhibition of splenic prion
(E) Co-labelling of ScNa2 cells with PrioV3 and ICSM18 (a mouse IgG anti-PrP antibody),
V3 binds to the prion inside the cytoplasm of ScN2a cells (orange arrow); in contrast
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113e120 [121]. These conformational changes are believed to play a
critical role for prion disease and transmissibility [124].
3.4.1. PrP speciﬁc nanobodies Nb484 and PrioV3: generation and
characterisation
Nb484 has been selected by phage display from the blood of
llamas immunised with recombinant murine PrP (MoPrP (23e230)
or murine PrP fragment MoPrP (89e230)). It was chosen among 14
nanobodies because it displayed the highest afﬁnity for recombi-
nant human PrP (HuPrP (23e231) and HuPrP (90e231)) [125]. Its
epitope is discontinuous and includes residues 123e125, the b2-a2
loop (residues 164e170) and half of the a2-helix (residues
174e185) (Fig. 6A).
PrioV3, a speciﬁc nanobody to PrP, has been isolated by phage
display from the blood of camels immunised with murine scrapie
material adsorbed onto immunomagnetic beads [126]. Its epitope
was identiﬁed via a pepscan approach by determining the ability of
PrioV3 to bind to a series of 20-amino acid peptides spanning the
region 99e230 of PrP. This analysis indicates that PrioV3 binds to a
linear motif within the C-terminal region of prion (i.e. residues
171e190), and of both PrPC and PrPSc before and after digestion by
proteinase K (Fig. 6A).
3.4.2. Nb484 as structural probe
Nb484 was used as a chaperone to crystallise for the ﬁrst time
the full length human PrP (HuPrPC) and its C-terminal truncated
version (residues 90e231) [125]. The X-ray diffracting crystal of
both PrP forms in complex with Nb484 revealed unprecedented
structural features at the N-terminal of the palindromic sequence.
Indeed, within the complex, about half of the palindromic
conserved motif AGAAAAGA adopts a fully extended b-strand
conformation (denoted b0) that constitutes a three-stranded anti-
parallel b-sheet with the b1 and b2 strands (Fig. 6B). The 128e225
segment shares a structure that is very similar to the corresponding
NMR structure of the free PrP although, upon the binding of Nb484,
the b1 extends from 3 to 7 residues and the b2-a2 loop is signiﬁ-
cantly stabilised; the 23e116 residues remain highly unstructured.
Therefore, this study demonstrated that the HuPrPC can adopt a
more elaborate b0-b1-a1-b2-a2-a3 structural organisation than the
prion-like b1-a1-b2-a2-a3 anti-parallel b-ribbon. The propensity of
the palindromic sequence to adopt a b-strand conformation sug-
gests that it is probably involved in the b-enrichment of the PrPC
monomer, and these conformational changes could therefore
constitute one of the early events of the conversion of PrPC to PrPSc.
3.4.3. Nb484 and PrioV3 as mechanistic probes
In vitro, Nb484 is able to slow down the aggregation into ﬁbrils
of murine MoPrP(23e230) in the presence of preformed murine
PrPSc seeds; the lag phase of aggregation kinetics is indeed
extended by a factor ~2 (~75 h versus 30 h in the presence and
absence of Nb484, respectively) [125]. Moreover, Nb484 also in-
hibits the prion propagation in vivo: scrapie infected murine cells
(ScGT1) treated with Nb484 show decreased PrPSc levels compared
to non-treated cells, the effect being Nb484 dose-dependent. In
cells treated with 3.5 mM Nb484, no PrPsc could be detected for at
least 7 days and even 14 days after removal of the nanobody from
the medium. It is not yet clearly determined if Nb484 inhibits the
prion replication by steric hindrance or by preventing structural
rearrangements that are essential for the formation of amyloido-
genic intermediates [125]. The stabilisation of the b2-a2 loop,
which is part of the epitope and whose ﬂexibility has been shown
to be important for prion infection, may be particularly relevant.
PrioV3 alters the PrPC expression and induces a signiﬁcant
reduction in PrPSc accumulation within the cells when added dailyin the tissue culture medium (Fig. 6C). It is not clear, however, if
these inhibitory effects are due to the recognition of PrPC and/or
PrPSc. Remarkably, the effects persist three days after the inter-
ruption of the addition of the nanobody [126]. Similar effects were
observed with prion-infected GT1 cells (ScGT1) [127]. Moreover, no
neurotoxic effects, measured by DNA fragmentation, were observed
following treatment of the cells with the nanobody. Since PrioV3
targets both PrPC and PrPSc, it could both block the conversion of
PrPC into propagating infectious agents and, at the same time, it
could neutralise the infectious template, PrPSc [126]. Finally, a
weekly injection of PrioV3 into mice, inoculated with scrapie-
infected brain homogenate, leads to a marked inhibition of PrPSc
accumulation in the spleen of the animal (Fig. 6D) [126].
3.4.4. PrioV3 is able to cross membranes
PrioV3 binds PrPC both at the cell surface and in the cytoplasm of
ScN2a cells without cell permeabilisation, indicating that it is able
to cross the cell membrane (Fig. 6E) [126]. The ability of the
nanobody to cross the blood brain barrier (BBB) was established
in vitro using two human BBBmodels. Moreover, following its intra-
venous injection, PrioV3 was widely distributed in the brain pa-
renchyma of rats, demonstrating that it can also cross the BBB
in vivo [126].
3.4.5. Conclusions
All together, these ﬁndings demonstrate the potential use of
anti-prion nanobodies for the treatment of prion diseases and to
better understand the molecular mechanism of aggregation.
Compared to conventional antibodies such as the anti-prion mu-
rine mAb ICSM35, PrioV3 presents two main advantages: (i) ﬁrst, it
crosses the cytoplasmic membrane and the BBB, at least in rats, and
can in consequence be active in cells and particularly in neurons,
and (ii) secondly, it is devoid of toxicity at least in neuronal cell
culture [126]. Moreover, Nb484 is an efﬁcient crystallisation
chaperone that has allowed getting for the ﬁrst time high resolu-
tion structural feature (1.5 Å) of a region of the protein encom-
passing part of the palindromic region: it forms new b-hairpin
(b0eb1) that can serve as a structural nucleus for the growth of
intermolecular b-sheets.
3.5. Polyadenylate binding protein nuclear 1 and oculopharyngeal
muscular dystrophy
Themost common form of oculopharyngeal muscular dystrophy
(OPMD) is an autosomal dominant disease that is caused by the
expansion of GCG trinucleotide repeats in the coding sequence of
the polyadenylate-binding protein nuclear 1 (PABPN1), translated
into a poly(Ala) stretch [128]. The wild-type protein bears 10 ala-
nines at its N-terminus; mutant proteins (mPABPN1) in which the
polyA tract is extended to 12e17 residues cause the disease and the
longer the tract the more severe the disease [128]. The character-
istic feature of OPMD is the presence of ﬁlamentous intranuclear
inclusions made of mPABPN1 and resistant to KCl treatment [128].
Although the exact pathological mechanism underlying OPMD is
still poorly understood, a body of evidence suggests that it is
associated, at least in part, with the formation of aggregates and
especially of oligomers or micro-aggregates made by the mutant
proteins [129,130]. Although probably all the skeletal muscles are
affected, the histologic changes are however most pronounced in a
limited set of skeletal muscles (i.e. extraocular, lingual, pharyngeal
and diaphragmatic muscles) [128]. OPMD usually starts in the ﬁfth
or sixth decade of life with the main symptoms being eyelid
drooping and difﬁculty in swallowing due to a weakness in the
levator palpebrae superioris and pharyngeal muscles, respectively
[129]. The disease does not shorten the life expectancy of the
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their life due to frequent aspiration pneumonia and difﬁculties in
swallowing which lead to malnutrition [128]. The largest OPMD
cluster is in French-Canadian population with an estimated
prevalence of 1:1,000; in Europe, the estimated prevalence is
1:100,000 [128].
PABPN1 is a nuclear ubiquitously expressed multifunctional
protein which is involved in pre-mRNA polyadenylation, tran-
scription regulation, and mRNA nucleocytoplasmic transport in
presumably all tissues [129]. It is a 306 residue multi-domain
protein (MM ~32.8 kDa) (Fig. 7A) that can be divided in three
domains [128,129]. (i) An acidic N-terminus domain (residues
1e161) starts with a stretch of 10 alanines. Moreover, part of thisFig. 7. Effects of the binding of 3F5 on the properties of PABPN1. (A) Domain structure of hum
that contains a stretch of 10 alanines (that is expanded to between 12 and 17 in the autosoma
polymerase, (ii) a RNA recognition motif that is required for poly-A RNA binding, and (iii) a
aggregation of PABPN1 by the nuclear expression of 3F5. Plasmids coding for mPABPN1-Ala1
the percentage of cells containing aggregates after 48 h was determined. The plasmid coding
a plasmid coding for NLS-GFP (ratio 1:1). The co-transfection with the 3F5-NLS-GFP plasmid
NS (not signiﬁcant) P > 0.05. From Ref. [134]. (C) Effect of the intramuscular expression
nanobodieswas determined by scoring the number of adults with abnormal wing position at
nanobody. The percentage of ﬂies with abnormal wing posture indicated are those of the tra
[136].domain (residues 119e146), which is essential for the interaction
of PABPN1 with the poly-A polymerase, is predicted to form a
coiled-coil structure (CC). (ii) A RNA recognition motif (RRM, res-
idues 162e257) which consists of four parallel b-sheets coupled
with two perpendicular a-helices. And (iii) a basic C-terminal
domain rich in dimethylated arginine (residues 258e306); this
domain contains a nuclear localisation signal (NLS). The protein
also contains two oligomerisation domains: one overlapping the
RNA binding domain (residues 155e294) and the other
comprising the NLS sequence (residues 264e306).
Both the wild-type and mPABPN1 are aggregation-prone but
only the mutant form is pathogenic. When bound to the poly-A
mRNA, PABPN1 forms in vitro, via its oligomerisation domains,an PABPN1. PABPN1 can be divided into three main domains: (i) an N-terminal domain
l dominant OPMD) and a coiled-coil (CC) regionwhich is required for binding to poly-A
C-terminal region that contains a nuclear localisation signal (NLS). (B) Inhibition of the
7 and 3F5-NLS-GFP were co-transfected in different ratios into HeLa and COS cells and
for mPABPN1-Ala17 was also co-transfected with a plasmid coding for a control VHH or
signiﬁcantly inhibits aggregation in a dose-dependent manner. *P < 0.05, **P < 0.01 and
of anti-PABPN1 nanobodies on the OPMD phenotype in Drosophila. The effect of the
days 6 and 11 at 18 C. Two to ﬁve independent transgenic lines were analysed for each
nsgenic line showing the lowest and highest effects with the same nanobody. From Ref.
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ticles which do not resist to KCl treatment contrary to the aggre-
gates formed by mPABPN1 [131]. Deletion of one of the
oligomerisation domains prevents the pathological aggregation of
the mutant form of PABPN1 containing 17 alanines (mPABPN1-
Ala17) into KCl-resistant aggregates [130,131]. This observation
indicates that, like for the aggregation of proteins containing a
polyglutamine tract, the regions outside the alanine repeat have
their own role to play [132] and suggests a multi-domain aggre-
gation mechanism. Differences in the aggregation kinetics and/or
pathway by the wild-type and mPABPN1 could explain their dif-
ferences in toxicity [133].
3.5.1. Generation and characterisation of PABPN1 speciﬁc
nanobodies
A series of PABPN1 speciﬁc nanobodies have been selected from a
large (5$109 individual clones) non-immune llama HCAb library us-
ing both recombinant human and bovine PABPN1 as panning anti-
gens [134]. A total of six different nanobodies with afﬁnities for
PABPN1 ranging from 5 to 57 nM were selected. The epitope of the
nanobodyexhibiting the highest afﬁnity (i.e. 5 nM), referred to as 3F5,
was mapped using a panel of truncated and point-mutation recom-
binant PABPN1 proteins. It is located between residues 113 and 132
which largely overlap with the region of the protein that is predicted
to form a coiled-coil domain (Fig. 7A), and residues 126, 129 and 131
are essential for thebinding of thenanobody. This conclusionwas also
supported by an NMR study [135]. Two other nanobodies (3A9 and
3E9) recognise an epitope in the 1e155 region, and the other three
(#08, #18 and #29) were selected by epitope-masking using 3F5
[136] and thus are likely to recognise an epitope different from that of
3F5. 3F5 detects PABPN1 in the nuclear fraction of HeLa cells [134].
Moreover, 3F5 labels the nucleus of cultured cells (HeLa and COS-1)
and human muscles on cryosections [134].
3.5.2. 3F5 expressed in cells affects in vivo aggregation
The effect of intracellular expression of 3F5 was investigated in
cellular PABPN1 aggregation models. A plasmid coding for 3F5 in
fusion with a nuclear localisation signal (NLS) and the green ﬂuo-
rescent protein (GFP), referred to as 3F5-NLS-GFP, was transfected
into COS-1 and HeLa cells. The GFP signal was observed only in the
nucleus, indicating both a successful expression of the nanobody
and its targeting into the nucleus [134]. In cells co-transfected with
a constant amount of plasmid coding for murine mPABPN1-Ala17
and an increasing amount of plasmid coding for 3F5-NLS-GFP, the
nanobody drastically prevents the aggregation of mPABPN1-Ala17
in a dose-dependent manner (Fig. 7B). Moreover, the expression of
the nanobody is not toxic for the cell (i.e. it does not modify the cell
viability) and does not affect the expression of mPABPN1-Ala17. The
decreased aggregation in the presence of 3F5 is therefore a direct
effect of the nanobody binding and is not due to a reduced amount
of the expressed mutant protein. The effects of 3F5 are due to very
speciﬁc interactions since the binding of the other PABPN1-speciﬁc
nanobodies recognising different epitopes does not inhibit the ag-
gregation [134]. Moreover, transfectionwith the plasmid coding for
3F5 in HeLa and COS cells already containing mPABPN1-Ala17
intranuclear aggregates, results in a signiﬁcant decrease in the
amount of the latter [134]). In another study, using U2OS cells, 3F5
was however found to reverse the formation oligomers but not that
of insoluble aggregates [133].
3.5.3. 3F5 expressed in an animal model
The effects of the six nanobodies were investigated in vivo using
a Drosophila model that recapitulates the characteristics of the
disease, in particular (i) muscle degeneration, the myoﬁbril sarco-
meric structure being strongly disorganised with broken Z-bandsand the absence of M-band, (ii) gene deregulation and (iii) forma-
tion of dense PABPN1 nuclear inclusions in muscle cells composed
of ﬁbrillar aggregates. These modiﬁcations cause an abnormal wing
posture [136]. The capacity of the six PABPN1 nanobodies to
decrease OPMD phenotypes in vivo was assayed by co-expressing
PABPN1-Ala17 with each of them in muscles using the Mch-Gal4
driver system. The capacity to decrease OPMD phenotype is
different for each nanobody (Fig. 7C). The nanobodies #08, #18 and
#29 have a very weak effect on suppressing abnormal wing posi-
tion. 3E9 and 3A9 have an intermediate effect, whereas 3F5 is very
effective in suppressing the abnormal wing posture (Fig. 7C), and its
effect is dose-dependent [136]. The lower efﬁciency of the nano-
bodies to decrease the phenotype was not correlated to a lower
expression level; it is likely that it is instead correlated with the
epitope they recognise and/or with their afﬁnity for PABPN1.
Moreover, 3F5 does not interfere with the aggregation process in
ﬂies expressing mutant PABPN1 in which the coiled-coil region has
been deleted, and does not rescue the disease phenotype of these
ﬂies [136]. Thus, the curative effects of 3F5 depend on its ability to
bind to the coiled-coil region of PABPN1 in vivo.
The co-expression of 3F5 with mPABPN1-Ala17 prevents muscle
degeneration in Drosophilia and restores a normal appearance of
the muscle ﬁbres [136]. It does not reduce the number of nuclei
containing aggregates; the size of the aggregates is however
reduced by a factor up to 2.5 and the aggregates formed are more
dispersed. These observations suggest that 3F5 could interfere with
intermediate species such as oligomers or micro-aggregates and
prevent their toxicity [136]. A transcriptome analysis showed that
the co-expression of 3F5 decreases the OPMD-induced gene
deregulation. This effect was the strongest in adults at day 2 but
persists during the whole lifespan of the animals [136]. All together
these results strongly suggest that the expression of the nanobody
prevents muscle degeneration in vivo by altering the nuclear ag-
gregation of mPABPN1-Ala17 and restoring gene expression. The
epitope of 3F5 is located in the coiled-coil region of the protein and
thus is also present on the wild-type protein. The expression of 3F5
in human cells could therefore potentially affect normal functions
of PABPN1 although it does not induce muscle degeneration in
Drosophila and does not reduce the viability of cell models.
3.5.4. Conclusions
These studies show that nanobodies can efﬁciently be expressed
intracellularly, in cell cultures andanimalmodels, in a functional form
using conventional expression vectors. Again, the easyengineeringof
the nanobodies are important (i) to direct the expression of the
nanobody in speciﬁc cellular compartments (i.e. by fusing it to an
addressing signal) and (ii) to fuse it to an imaging agent (i.e. the GFP).
3.6. Ab peptide and Alzheimer's disease
Alzheimer's disease (AD), the most common neurodegenerative
disorder, is characterised by two features: (i) the intraneuronal
accumulation of hyperphosphorylated tau protein in the form of
neuroﬁbrillary tangles, and (ii) the formation of extracellular am-
yloid plaques, composed of the Ab peptide (also referred to as senile
plaques) in the central nervous system [137,138]. The accumulation
of these aggregates, or some of their precursor oligomeric species,
is thought to cause the loss of neurons, notably in the hippocampus,
leading to memory deﬁciency and cognitive dysfunctions [139]. Ab
peptides arise from a proteolytic cleavage of the transmembrane
glycoprotein amyloid precursor protein (APP) following the action
of two secretases [140]. First, the b-secretase generates the APPsb
fragment (secreted in the plasma) and the C99 fragment (still
membrane anchored) [141]. This latter is then cleaved by the g-
secretase into a variety of peptides including the amyloidogenic
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a-secretase and this leads to the production of non-amyloidogenic
peptides.
Ab peptides are produced in the brain and the cerebrospinal
ﬂuid (CSF) of healthy humans; Ab40 is the most abundant
secreted species, while Ab42 has a stronger tendency to aggregate
and is believed to be the ﬁrst species to deposit in senile plaques
[142e144]. No precise physiological role is yet known for Ab
peptides but a study has shown that Ab modulates synaptic
strength while its production and secretion are regulated by
neuronal activity. Thus, Ab could have a negative feedback
function and may play a role in normal synaptic physiology [145].
In affected patients, the over-production of Ab peptides or an
increased proportion of Ab42 relating to Ab40 appear sufﬁcient to
cause the disease [146]. It was proposed that the Ab42:Ab40 ratio,
rather than the absolute amounts of the two peptides, is critical
for the induction of neurotoxic conformations [147]. In addition
to sporadic AD, an early-onset familial form of the disease has
also been described and is associated with genetic mutations.
More than 230 mutations in g-secretases (i.e., presenilins PS1Fig. 8. Effects of the binding of nanobodies on the properties of Ab-peptide. (A) Schematic r
KW1AP interacts with oligomers through a hydrophobic and signiﬁcantly aromatic surface m
terminus of Ab. The main mutations that are associated with familial AD are also shown. (B)
code 3LN9) with amyloid-like steric zipper structure (PDB code 2ONV). CDR1, CDR2 and CDR
for B10. KW1AP interacts with Ab oligomers through a signiﬁcant proportion of hydrophob
surface. From Refs. [155,158]. (CeD) Kinetics of ﬁbril formation by Ab40 monitored by ThT ﬂ
aggregates, even at a substoichiometric ratio (KW1AP:Ab40 ¼ 1:5, 1:10 and 1:50). In the prese
after 160 h of incubation at 37 C. From Ref. [155]. (D) In the presence of B10, even at a rat
curvilinear protoﬁbrils. From Ref. [154]. Therefore, KW1AP and B10AP both prevent the fo
gregates or by stabilising the protoﬁbrils respectively. (E) Immunoreactivity of V31-1eCH2 (l
labels vesicles in the cytoplasm of granular cells of the dentate gyrus and dendritic shafts in
the phosphatase alkaline activity, shows plaques (>10 mm) on hippocampal sections of AD p
brain). From Ref. [154].and PS2) and in APP genes, including the Ab-peptide sequence
(Fig. 8A), have been identiﬁed, leading to an excessive production
of Ab peptides and/or to an increased propensity of the mutant
peptides to aggregate [148,149]. Nowadays, within the United
States, AD is the 6th leading cause of death [150].
Ab peptides are assumed to have an a-helical conformation as
part of APP in the membrane. By contrast, when released in solu-
tion, they seem to predominantly adopt unstructured conforma-
tions that only transiently form helical secondary structure
elements [151]. On the in vitro pathway of ﬁbril formation by Ab42,
several intermediate species are formed, including SDS-stable
oligomers, Ab-derived diffusible ligands (ADDLs) and protoﬁbrils.
It is now widely accepted that these soluble pre-ﬁbrillar as-
semblies are more cytotoxic to neurons while ﬁbrillar aggregates
may not play the main role in pathogenesis [146,152]. The Ab
peptide ﬁbrils consist in a layered structure in which three cross-b
subunits are arranged in six tightly stacked b-sheet layers with an
anti-parallel hydrophobicehydrophobic (residues 30e40) and an
anti-parallel polarepolar interface (residues 10e22) [153].epresentation of APP and Ab peptide highlighting the binding sites of KW1 and V31-1.
otif that includes Ab residues 18e20. The epitope of V31-1 is comprised within the C-
X-ray crystal structures of KW1 (Left panel, PDB code 3TPK) and B10 (Right panel, PBD
3 are coloured respectively in blue, green and pink for KW1, and in red, blue and green
ic amino acid side chains while the antigen biding site of B10 basically exhibits a ﬂat
uorescence and by TEM. (C) KW1AP interferes with the formation of Ab40 ThT-positive
nce of KW1AP, Ab40 forms non-ﬁbrillar aggregates while Ab40 alone forms mature ﬁbril
io 1:10, the Ab40 peptide does not form ﬁbrils; instead it aggregates into irregular and
rmation of mature Ab ﬁbrils, either by inducing the accumulation of non-ﬁbrillar ag-
eft) and B10AP (right) against the Ab peptide in an AD patient brain tissue. V31-1eCH2
hippocampal pyramidal neurons (arrow). From Ref. [152]. B10AP staining, visualised via
atients (blue arrows) but not in the controls without clinical signs of dementia (control
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A series of nanobodies, speciﬁc to particular Ab peptide species
(i.e. monomers, oligomers and/or ﬁbrils), have been generated and
characterised in detail; they are referred to as B10 [154], KW1 [155],
V31-1 [152], PrioAD12 and PrioAD13 [127] and ni3A [156].
3.6.1.1. B10 and KW1. B10 and KW1 have been retrieved from fully
synthetic libraries coding for nanobodies, using respectively
partially biotinylated ﬁbrils and oligomers of Ab40 as targets,
immobilised on the surface of streptavidin-coated magnetic beads
[154,155]. The selectionwas carried out in the presence of a 10-fold
molar excess of freshly disaggregated Ab40 peptide (i.e. largely
monomeric) in order to avoid the selection nanobodies that bind to
the monomeric form of Ab40. B10 and KW1 were fused to Escher-
ichia coli alkaline phosphatase (AP), a homodimeric protein, and the
bivalent chimeric proteins are called respectively B10AP and
KW1AP. The advantage of using these chimeras is threefold: (i) they
have a higher apparent afﬁnity for their respective epitope than B10
and KW1, (ii) they increase the solubility of the nanobodies, and (iii)
the AP moiety serves as reporter (based on an enzymatic colour
assay) for the detection of nanobodies in immuno-blot and immu-
nochemistry without the need to use a secondary antibody, and for
transmission electron microscopy (based on the catalysis of the
formation of cerium phosphate, an electron-dense precipitate that
accumulates in the vicinity of the active site). Here, again, the
easiness with which nanobodies manifold constructs can be engi-
neered constitutes an important advantage.
3.6.1.2. V31-1. V31-1was selected, using Ab42 as bait, from a library
made from the blood of a llama immunised with Ab42 incubated
overnight at 37 C, corresponding to a mixture of monomers,
oligomers and ﬁbrils [152]. As B10 and KW1, this nanobody was
engineered as a multifold construct for imaging purpose; it was
fused to the CH2 domain of an alpaca HCAb (V31eCH2) for im-
munostaining studies (Fig. 8E). The signal could therefore be
ampliﬁed using rabbit anti-alpaca Ig polyclonal antibodies as sec-
ondary antibodies which are labelled by an anti-rabbit biotinylated
goat polyclonal antibody. The streptavidin-peroxidase complexes
could then be revealed with diaminobenzidine [152].
3.6.1.3. PrioAD12 and PrioAD13. PrioAD12 and PrioAD13 were iso-
lated from a library made from the blood of three alpagas immu-
nised with homogenised brain of an AD patient absorbed
immunomagnetic beads [127]. PrioAD12 is speciﬁc of Ab40 while
PrioAD13 is speciﬁc of Ab42.
3.6.1.4. ni3A. ni3A was isolated from a non-immune llama-derived
phagemid library and selected by phage display against Ab42 [157].
Two successive rounds of selection were performed, using coated
synthetic Ab42 as target. ni3A recognises Ab42 with a high afﬁnity
(KD ¼ 39 nM) while it does not bind to Ab40.
3.6.2. Ab nanobodies as structural probes
3.6.2.1. V31-1 speciﬁcally binds to monomers and small oligomers
(from dimers to 12-mers) of Ab. V31-1 has a high afﬁnity for Ab42
(KD ~30 nM) and does not recognise the Ab40 peptide nor the 1e11,
10e20,15e25 and 22e35 peptides fromAb [152]. However, it binds
to the 29e40 and 33e42 fragments, suggesting that it recognises an
epitope located at the C-terminal end of Ab peptide. Moreover, V31-
1 was found to be able to bind to monomers, dimers, trimers and
tetramers as well as 12-mers but not higher molecular mass, SDS-
insoluble, oligomers nor ﬁbrils, suggesting that in these species the
C-terminus is not accessible. The high speciﬁcity of this nanobody
for low-MM oligomers made of Ab42 suggests that it could have agreat potential for diagnosis and detection of Ab oligomers in pa-
tients' brains.
3.6.2.2. KW1 speciﬁcally binds to Ab40 oligomers. KW1 is speciﬁc to
Ab40 oligomers: it does not bind to ﬁbrils nor to disaggregated Ab40
peptides [155]. It interacts preferentially with non-ﬁbrillar and
often heterogenous high-MM Ab40 oligomers which have an
isotropic shape and diameters of 8e30 nm. Remarkably, KW1AP
does not bind to Ab42 oligomers although these cannot be differ-
entiated from Ab40 oligomers by Fourier transform infrared spec-
troscopy (FTIR) and TEM. KW1 can therefore probe very subtle and
surface-inherent properties of oligomers. The X-ray structure of
KW1 shows that it possesses a large hydrophobic cavity that is
exposed to the solvent (Fig. 8B). The binding properties of KW1AP
with a series of Ab40 mutant peptides, in combination with peptide
spot arrays and NMR studies, suggest that it interacts with oligo-
mers through a hydrophobic and signiﬁcantly aromatic surface
motif that includes Ab residues 18e20 (Fig. 8A).
3.6.2.3. B10 is speciﬁc to protoﬁbrils and ﬁbrils. B10 speciﬁcally
binds to protoﬁbrils and mature amyloid ﬁbrils formed by the Ab40
peptide. Its afﬁnity (i.e. KD) for Ab40 amyloid ﬁbrils, determined by
SPR, is ~475 nM, and the stoichiometry of binding is 1:10 (B10:Ab40).
The afﬁnity of B10AP, which is bivalent, is 50-fold higher (i.e. KD
~7.2 nM) [154]. B10 does not recognise other conformers of the Ab
peptide such as disaggregated peptides or non-ﬁbrillar Ab oligo-
meric species exhibitingaveryhighb-sheet content similar to thatof
amyloidﬁbrils [154]. The presence of a b-sheet structure is therefore
not sufﬁcient to explain the B10 binding. Interestingly, B10 is able to
bind to different types of amyloid ﬁbrils formed in vitro by Ab40 and
Ab42 under different conditions of incubation. B10 also binds to: (i)
ﬁbrils formed in vitro from a broad range of amyloid proteins (i.e.
insulin, glucagon, b2m), and to amyloid ﬁbrils from D-amino and L-
amino acid peptides; (ii) tissue-extracted amyloid ﬁbrils composed
of serum amyloid A (SAA) protein and Ig light chain (AL) [24]; (iii)
hippocampal sections from Alzheimer's patients (Fig. 8E)[154].
Importantly, these observations indicate that ﬁbrils formed in vitro
and in vivo, at least by the Ab peptide, do share some basic structural
features. The B10-epitope density at the surface of the ﬁbrils as well
as B10AP staining intensity both vary, however, for the different ﬁ-
brils. More importantly, B10 does not recognise e at all e some
amyloid ﬁbrils formed in vitro (i.e. ﬁbrils made of Ab16e22, apo-
myoglobin and PABPN1), nor some amyloid tissues deposits [24].
The recognition of amyloid ﬁbrils by B10 cannot, therefore, solely be
explained by an amyloid-speciﬁc polypeptide fold since, despite
their common backbone conformation, not all amyloid ﬁbrils are
recognised by B10 [24].
The easiness with which mutations can be introduced in the
gene of nanobodies and with which nanobodies can be produced in
large quantities allowed a large number of mutants (i.e. 23 variants
corresponding to single-site mutagenesis of the 23 residues within
CDRs 1e3) to be produced and characterised, in order to under-
stand the molecular basis of the speciﬁcity of B10 [158]. The results
of this systematic mutagenesis approach show that the basic resi-
dues (positively-charged residues) belonging to CDRs create a
strongly positive electrostatic potential at the B10 binding surface,
leading to electrostatic interactions with anionic groups present on
some ﬁbril surfaces. Moreover, the binding of B10 to amyloid ﬁbrils
composed of Ab40, insulin and G-helix peptide from sperm whale
myoglobin is signiﬁcantly reduced when the carboxyl groups of the
ﬁbrils are chemically modiﬁed [158]. The conformational speciﬁcity
of B10 for amyloid ﬁbrils seems therefore to depend upon speciﬁc
electrostatic interactions with highly regular and anionic surface
pattern common, at least locally, to different but not all amyloid
ﬁbrils, and not on the recognition of an amyloid generic backbone
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three CDRs constitute a positively charged ﬂat surface (Fig. 8B)
[158]. The B10 molecular recognition reaction can therefore be
described as an association between two relatively ﬂat but com-
plementary surfaces exhibiting opposite charges [158].
3.6.3. Ab nanobodies as mechanistic probes
3.6.3.1. B10 blocks amyloid ﬁbril formation at the protoﬁbril stage.
The binding of B10AP to preformed Ab ﬁbrils does not lead to
their signiﬁcant disaggregation. Moreover, in the presence of B10
(even at a ratio 1:10), the Ab40 peptide does not form amyloid
ﬁbrils instead, it aggregates into irregular and curvilinear proto-
ﬁbrils (Fig. 8D). The latter species display an amyloid-like cross-b
core structure with a higher susceptibility toward proteolytic
digestion than mature ﬁbrils, and they interact only weakly with
ThT or Congo red (CR). B10 therefore prevents the formation of
mature amyloid ﬁbrils by arresting ﬁbril formation at the proto-
ﬁbril stage. The fact that B10AP binds both protoﬁbrils and
mature amyloid ﬁbrils suggests that these two species possess the
B10 epitope at their surface. Kinetics of Ab40 ﬁbril formation
monitored both by ThT ﬂuorescence and dot-blot experiments
with B10AP indicate that the formation of this epitope preceeds
the formation of ThT-positive ﬁbrils. B10 is therefore likely to
inhibit the formation of mature ﬁbrils by preventing the self-
association of protoﬁbrils [154].
3.6.3.2. KW1AP prevents the formation of mature amyloid ﬁbrils and
leads to the formation of non-ﬁbrillar aggregates. KW1, which is
speciﬁc to high-MM Ab40 oligomers, interferes with the formation
of Ab40 ThT-positive aggregates, even at a substoichiometric ratio
(KW1AP:Ab40 ¼ 1:5, 1:10 and 1:50) (Fig. 8C). The presence of both
KW1AP (Fig. 8C) and KW1 signiﬁcantly increases the lag phase of
the Ab40 aggregation kinetics, suggesting that (i) the presence of
the alkaline phosphatase moiety does not perturbs the effects of
the nanobody and (ii) the effects of KW1 is similar weather it is
monomeric or dimeric (in KW1AP). Although the aggregates
formed in the presence of KW1AP or KW1 bind ThT, they appear as
non-ﬁbrillar by TEM analysis [155,159]. Moreover, they exhibit a
higher surface hydrophobicity than the ﬁbrils formed in the
absence of KW1, as revealed by an increased anilino naphthalene-
sulfonic acid (ANS) binding. Finally, as B10, KW1AP does not
signiﬁcantly disaggregate preformed Ab amyloid ﬁbrils [155].
3.6.3.3. V31-1 inhibits amyloid ﬁbril formation. When present at an
equimolar ratio, V31-1, which speciﬁcally binds to monomers, di-
mers, trimers, tetramers and 12-mers of Ab42, inhibits the forma-
tion of Ab42 amyloid ﬁbrils. Dynamic light scattering (DLS)
experiments indicate that, in the presence of an equimolar con-
centration of V31-1, Ab42 forms low-MM aggregates (RH of
10e25 nm and 150e200 nm). However, high-MM species (RH of
600e700 nm) formed in the absence of V31-1 are not observed.
This suggests that this nanobody prevents the formation of high-
MM aggregates [152].
It should be noted that several conventional antibodies are
raised against Ab oligomers; most of them however also bind to
ﬁbrils [160e162] and are therefore less speciﬁc than V31-1. More-
over, other antibodies that are speciﬁc to the C-terminus of Ab42 do
not inhibit the aggregation [163], contrary to V31-1. Altogether,
these observations suggest that V31-1 binds to an epitope that is
not recognised by conventional antibodies because it is less
immunogenic or less accessible. It has been suggested that the C-
terminus of Ab42 is more rigid than that of Ab40, may be reﬂecting a
pre-ordered structure for the acquisition of the b-conformation
present in soluble oligomers and ﬁbrils [164]. The Ab42 C-terminus
may therefore act as an internal seed for aggregation and V31-1,that could recognise such a structure in oligomers, is thus able to
inhibit the formation of ﬁbrils [152].
3.6.4. Nanobodies to detect Ab in cells and tissue biopsies
The distribution of V31-1-speciﬁc immunoreactivity in brain of
patients with AD shows that this nanobody binds mostly intra-
neuronal Ab peptides and stains only faintly extracellular amyloid
plaques or neuroﬁbrillary tangles [152]. Western-blot immunoas-
says, performed on formic acid fractions obtained from AD brains,
further indicate that V31-1 detects Ab oligomers in brain tissues.
KW1AP binds to oligomeric species derived from occipital and
temporal brain regions of an AD patient. B10 detects amyloid ﬁbrils
in tissue biopsies, although it stains only a small fraction (24%) of
the large series (106) of amyloid samples originating from a large
variety of organs and types of amyloidosis [165]. PrioAD12 efﬁ-
ciently binds to Ab plaques on brain sections from a patient with
AD; but no staining is observed with control brain [127]. Moreover,
staining of AD brain sections with FTIC-labelled PrioAD12 and texas
red-labelled lysosomal-associated membrane protein 1 co-localise
suggesting that the species recognised by PrioAD12 are located in
the late endosomal/lysosomal compartment [127]. All together,
these results indicate that some of the nanobodies could be very
useful as diagnostic tools.
3.6.5. Effects of nanobodies on the Ab toxicity
V31-1 prevents the Ab-oligomers induced toxicity towards SK-
N-SH cells, probably by preventing their interaction with the cells
[152].
The co-expression of B10 with a series of Ab-peptides (Ab40,
Ab42, Ab42Arctic (Fig. 8A)) in Drosophila melanogaster does not result
in any phenotypic changes compared to the expression of the Ab-
peptides alone [159] despite the facts that B10 (i) is able to bind
ﬁbrils formed in vitro by the three peptides and (ii) promotes,
in vitro, the formation of protoﬁbrils instead of ﬁbrils.
When added to a suspension of in vitro preformed Ab40 oligo-
mers, KW1AP antagonises the toxicity of the latter: they are not
able anymore to disrupt synaptic plasticity and perturbs long term
potentiation (LTP) in cultured murine brain slices [155]. The anti-
body is thought to act by preventing the binding of oligomers to
cellular surfaces or receptors. However, oligomers formed in vitro in
the presence of KW1 are highly toxic: they reduce the synaptic
potentiation in murine brain slices and the metabolic activity of
human neuroblastoma [159]. Similarly, when co-expressed in ﬂies
with Ab40, KW1 promotes toxicity: the median survival time of ﬂies
expressing both KW1 and Ab40 is 28 ± 1.1 days while that of ﬂies
expressing only Ab40 or KW1 is respectively 43 ± 0.6 and 41 ± 0.9
days [159]. The toxicity observed with oligomers formed in the
presence of KW1 is likely due to the fact that these oligomers
expose a more hydrophobic surface that favour their interaction
with cellular surfaces or receptors (see above).
In summary, these studies show that KW1 can prevent or
enhance Ab toxicity depending on the context and especially on the
time point in the aggregation process at which it is added. It may
block the binding of preformed oligomers to their cellular receptors
thus inhibiting their toxicity; but it can also modulate the peptide
self-assembly reaction and leads to the formation of more toxic
species. The biological consequence of a nanobody, and probably of
any ligand, is therefore difﬁcult to predict and this highlights the
complexity in developing therapeutic strategies to treat
amyloidoses.
3.6.6. ni3A crosses the BBB
ni3A signiﬁcantly transmigrates across a model BBB in vitro at
37 C [157]. On the other hand, ni8B, a nanobody that differs from
ni3A by only three amino acids in the N-terminus at positions 13,14,
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three amino acids, which are unusual for VHHs, play a critical role.
To elucidate the role of these amino acids, a chimeric nanobodywas
created; it consists in the sequence of va2E, a nanobody that cannot
signiﬁcantly cross the model BBB, in which the FR1 containing the
three unusual amino acid has been replaced by that of ni3A [156].
The chimeric protein has a signiﬁcantly higher transmigration rate
compared to the parental va2E, indicating that the three amino
acids that originate from ni3A facilitate the efﬁcient BBB crossing of
the nanobodies. The rate of model BBB crossing of the chimeric VHH
was however much lower than that of ni3A, indicating the other
features of ni3A were responsible of this property. The high per-
centage of charged amino acids of ni3A could explain, at least in
part, why ni3A outperforms other nanobodies in crossing the model
BBB. Moreover, there was almost no transmigration of ni3A across
the barrier at 4 C, suggesting that it crosses the BBB by an active
transport.
4. Prospects for diagnostic and therapeutic applications
Amyloidoses are particularly difﬁcult to diagnose. In the case of
systemic amyloidoses, most of them are rare and the symptoms can
be very broad and are often mimicked by more common disorders;
the deﬁnitive diagnostic is currently established after analysis of
biopsied tissues by Congo red binding and immunostaining. In the
case of AD and PD, such a deﬁnitive diagnosis has traditionally be
made by post-mortem histological analysis of brain tissue although
recent brain imaging have the potential to detect preclinical
anatomic and functional changes as well as protein deposition in
the brain [166,167]. Moreover, there is a body of evidence showing
that protein deposition and irreparable damages occur many years
before the signiﬁcant symptoms appear [167]. Thus, the treatment
of patients should ideally start before the apparition of symptoms
and this requires novel diagnostic methods, preferably non-
invasive, allowing an early detection of these diseases [156]. Li-
gands that are sensitive and selective for amyloid ﬁbrils or their
precursor species are of special interest to detect preclinical pa-
thology. In this context, the use of conformational antibodies is of
particular interest.
According to the amyloid cascade hypothesis, proteinmisfolding
and aggregation are the key events in triggering the disease. Thus
several therapeutic approaches targeting these phenomena are
being considered including: (i) reducing the expression level of the
amyloidogenic protein, (ii) increasing the clearance of the mis-
folded amyloidogenic proteins, (iii) increasing the stability of the
properly folded amyloidogenic proteins, (iv) neutralising the cyto-
toxic species, and/or (v) inhibiting or reversing the aggregation of
misfolded proteins into oligomers and ﬁbrils. A large body of
studies, in addition to those described in the previous section,
carried out both in vitro and in animal models has shown that an-
tibodies or antibody fragments can, at least, mediate the last three
effects [21,163,168] and improve the cognitive deﬁcit [163,169].
Despite these promising results obtained in the laboratory, clinical
trials involving active (i.e. injection of the antigen to induce the
production of antibodies) or passive (i.e. administration of speciﬁc
antibodies) immunotherapies did not, however, lead to the ex-
pected effects [170]. These observations actually reﬂect, once more,
the difﬁculty of predicting the effects of an antibody depending of
the context; theories why these failures occurred include late stage
disease treatment and poor penetration of antibody in the brain.
Immunotherapy, especially to treat AD and PD, is nevertheless still
a very active ﬁeld of research for which several new clinical trials
are ongoing [170,171]. Based on the results of previous works,
recent studies are reﬁning the selection of speciﬁc epitopes for
active immunisation and developing strategies to increase theability of antibodies to cross the BBB for passive immunisation
[170].
In case of passive immunotherapy, the main challenges are the
following: (i) How to deliver the antibodies where they need to act?
(ii) In case of disease associated with intracellular aggregates and/
or aggregation in the brain, antibodies must be able to respectively
penetrate into the cells and be active in the cellular environment
and/or to cross the blood brain barrier. (iii) The antibody should not
be toxic or immunogenic. The studies presented in the previous
sections are a proof of concept that nanobodies can target each
species formed on the pathway of ﬁbril formation and interfere
with each step of the aggregation process (Fig. 1). Some of these
effects have even been shown in vivo. This clearly demonstrates the
therapeutic potential of nanobodies. In the last section, we will
further show that, due to their unique properties, nanobodies are
promising to address the challenges mentioned above from both a
diagnostic and therapeutic point of view.
4.1. Nanobodies are efﬁciently produced intracellularly and can
cross membranes and the BBB
As mentioned above, in case of amyloidoses associated with
intracellular aggregates and/or aggregation in the brain, antibodies
must be able to respectively penetrate into the cells and be active in
the cellular environment and/or to cross the BBB.
Antibodies that function inside the cells are called intrabodies.
The function of conventional antibodies or antibody fragments
inside the cell is generally compromised due to the inability of the
disulphide bonds to form in the reducing environment of the
cytoplasmic environment and thus the inability of the protein to
fold or remain folded in its native state. Due to the high stability of
nanobodies [37], their conserved disulphide bridge can in many
cases be deleted without signiﬁcantly affecting their functionality
[71] and nanobodies fold well into functional entities in the
reducing intracellular environment [172]. Given this intracellular
robustness, combined to the easiness with which they can be fused
to signal peptides to direct them to speciﬁc cellular compartments,
nanobodies have been used for a variety of purposes in cells
including imaging [172e174]. Another major obstacle to antibody
applications in therapies is the delivery of the antibody at a sufﬁ-
cient concentration and to sufﬁcient number of target cells for a
sufﬁcient time. Strategies to continuously deliver recombinant
antibody fragments as genes is an increasing developing ﬁeld and
could easily be transferred to nanobodies [175].
Conventional antibodies cannot traverse cell membranes and
are not able to signiﬁcantly freely diffuse across BBB. Indeed, only
0.1e0.2% of circulating antibodies are found in brain at steady state
concentrations [176]. In addition to the PrioV3 and ni3A described
above, several other nanobodies able to cross the BBB have been
reported [157,172,177e181]. The amount of transduced nanobodies
as well as the mechanism by which they are transduced, varie
signiﬁcantly form one sequence to another. And despite the
increased intake level, there is still a debate whether the trans-
duced amount of nanobodies is sufﬁcient to allow imaging and
therapy [172,182]. Again, due to their small size, high stability and
easiness to be engineered, the various approaches that have been
reported to transduce proteins (i.e. coupling them to a shuttle
peptide or protein to facilitate their passage through the BBB via
receptor mediated transcytosis) should be easily transferable to
nanobodies.
4.2. Nanobodies as powerful imaging tools
Given the high stability of nanobodies, a large number of label-
ling strategies are possible including the use of radionulei [183],
C. Pain et al. / Biochimie 111 (2015) 82e106102near-infrared ﬂuorophores [184] and ﬂuorescent proteins [182].
Nanobodies fused to a ﬂuorescent protein (e.g. mRFP and GFP),
referred to as chromobodies, have been extensively used as a
research tool to recognise and trace their speciﬁc antigen in
different subcellular compartments [172,173]. Such chromobodies
can be expressed throughout an organism allowing the localisation
of their speciﬁc targets within the cell; this approach is of particular
interest given the recent consideration in the amyloid ﬁeld that
aggregates of a series of proteins behave as prions and can move
between cells [17]. Moreover, by coupling nanobodies that are
speciﬁc to the different species formed upon ﬁbril formation (i.e.
misfoldedmonomers, oligomers and ﬁbrils) to different ﬂuorescent
proteins, one should be able to follow simultaneous the evolution
these species in time and space.
The critical features of an in vivo imaging agent are: stability
in vivo, rapid reaching and interaction with its target, high target to
background ratio, fast elimination of unbound molecules from the
body, minimal non-speciﬁc accumulation in tissues surrounding
the molecular target and low immunogenicity. These features are
essentially all fulﬁlled by nanobodies [185,186] and a series of
studies suggest that nanobodies could become the next generation
of magic bullets for immune-imaging [182,187]. For example, radio-
labelled nanobodies that are speciﬁc to carcino embryonic antigen
(i.e. the epidermal growth factor and the HER2 receptor expressed
on cancer cells) show rapid (i.e. 1 h after injection) and speciﬁc
uptake in mouse tumour model [187]. Due to the high speciﬁcity,
high tissues penetrance and short biological half-life of the nano-
body, imaging with sufﬁcient contrast is possible shortly after its
injection which, from a practical point of view, will be much
appreciable for the patients. It also allows the use of short-lived,
and thus less toxic, radionuclei [187].4.3. Immunogenicity and humanisation of nanobodies
Non-human antibodies may trigger an immune reaction in
humans, limiting their use, especially for prolonged therapeutic
applications involving multiple administrations. Thus, non-human
antibodies need to be “humanised” to be accepted as human
therapeutics; that is their sequence has to be modiﬁed to increase
their similarity to antibody variants naturally produced in humans.
Since all nanobodies belong to the same sequence family which is
closely related to the human VH of family III (i.e. they show ~80%
sequence homology with the human family III when comparing the
framework regions [40]), they should exhibit low immunogenicity.
And indeed, so far, no immune adverse events have been reported
in clinical studies [33]. Moreover, if necessary, their humanisation
(i.e. mutation of speciﬁc residues to their human VH equivalent) is
rather straightforward since a nanobody differs from a human VH (i)
in four hallmark nanobody-speciﬁc amino acids located in the
framework 2 which normally interacts with the VL domain in
conventional antibodies (positions 42, 49, 50 and 52) and (ii) in
about 10 amino acids, outside the framework 2, spread all over the
surface of the nanobody. The group of S. Muyldermans has estab-
lished two strategies to efﬁciently humanise nanobodies without
signiﬁcantly affecting their binding speciﬁcity, stability and solu-
bility [188]. The ﬁrst strategy consists in mutating the 10 surface
residues and 2 nanobody-speciﬁc FR2 residues (positions 49 and
50). The second strategy consists in grafting the CDRs of the
nanobody of interest onto a universal humanised nanobody scaffold.
The latter has been designed using the ﬁrst strategy (i.e. by
mutating 10 surface residues and residues at positions 49 and 50)
on cAb-BcII10, a nanobody which has very favourable properties
including high stability, high yield of production [37], and a high
tolerance to CDR grafting [72].5. Conclusions
As summarised in Fig. 1, the results reported in this review
clearly demonstrate that nanobodies, from different origins (i.e.
from immune, non-immune or synthetic libraries) could target
each species formed on the pathway of ﬁbril formation. Moreover,
their binding to their speciﬁc target can inhibit ﬁbril formation at
various stages ranging from the ﬁrst step (i.e. inhibition of the
formation of the amyloidogenic intermediate via the stabilisation of
the native state) to the self-association of protoﬁbrils. Importantly,
when not adapted to the conditions used to trigger amyloid ﬁbril
formation, the properties of nanobodies can easily be improved by
protein engineering. Moreover, manifold constructs, for example
fusion to an enzyme or GFP, can readily be generated to enable easy
imaging both in vitro and in vivo. These studies also demonstrate
that nanobodies are unique structural probes. They can trap species
that are only transiently populated (i.e. the aggregation nucleus)
and they can be used as crystallisation chaperone to obtain, at high
resolution, structural information about these species. Finally, they
are able to target very sensitive/discrete differences between
various populations of oligomeric species or amyloid ﬁbrils which
cannot be distinguished by standard techniques (i.e. TEM, FTIR,
NMR). These studies highlight the importance of nanobodies as
unique and powerful research tools to better understand the
complexity of ﬁbril formation and the associated toxicity both
in vitro and in vivo, and thus to identify and validate drug targets.
Given their small size, high stability, easiness to label and better cell
and BBB penetration, nanobodies constitute valuable imaging tools.
Again, due to their unique properties, nanobodies constitute an
additional therapeutic approach for amyloidoses although the
question of efﬁcient delivery to the brain remains to be solved. The
ﬁeld of applications of nanobodies is expending at an impressive
rate and transferring the knowledge gained form these studies,
especially in terms of engineering, to the ﬁeld of amyloidoses holds
good premise for further developments of nanobodies to study,
diagnose and eventually treat amyloidoses.
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